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ABSTRACT

ANTIDIABETIC ACTIVITY OF CISSUS ROTUNDIFOLIA PLANT GROWING IN
SAUDI ARABIA

SAAD ALSHEHRI
2020

Diabetes mellitus (DM) is a metabolic disease characterized by high levels of blood
glucose resulting from defects in insulin production or action. A world-wide increase in
the diabetes rate is projected to reach pandemic levels over the next 10-20 years. Current
data shows that high numbers of the population in Saudi Arabia suffer from diabetes and
prediabetes. Non-traditional treatments of diabetes from medicinal plants has shown
potential antidiabetic activity. A considerable percentage of the population still prefer or
use medicinal plants as a treatment or supplement to traditional medicine. Cissus
rotundifolia (family Vitaceae) is a known plant in southwestern Saudi Arabia used by
people in the region to treat skin diseases, burns and diabetes. The chemical and
biological characteristics of Cissus rotundifolia’s active compounds are unknown. The
aim of this study to investigate the chemical and biological properties of this medicinal
plant using bio-assay guided separation. Aqueous methanol extract of Cissus rotundifolia
was fractionated by partitioning against hexane and ethyl acetate. Methanol, ethyl acetate
and hexane extracts were then screened for antidiabetic activity using an alphaglycosidase assay at a concentration of 12.5-50 mg/ml. Methanol extract showed a
significant alpha-glucosidase inhibition percent of 58-95%. Further, LC separation

xvi
afforded six compounds isolated and characterized using 1H-NMR, 13C-NMR and
2DNMR. Two of the isolated compounds: 3 and 4 (1,4-dimethyl 2-hydroxybutanedioate
and 3-hydroxy-4-methoxy-4-oxobutanoate, respectively) showed a significant inhibition
of alpha-glycosidase enzyme in the range of 25% to 50% at a concentration range from
1.00 – 0.25 mg/ml. Also, since glucose uptake is considered one of the main pathways to
control blood sugar levels, the fractions and the isolated compounds were investigated for
their glucose uptake activity. Glucose uptake assay results showed that the ethyl acetate
fraction has a significant uptake activity. The isolated compounds 3 and 4 showed
increased of glucose uptake activity reach of 19 % and 25%, respectively, with Insulin
used as the positive control. Structural similarities of isolated compounds to malate which
is a main substrate of citric acid cycle, prompted us to build hypothesis that these
compounds might interfere with gluconeogenesis process through inhibition of the citric
acid cycle. Molecular modeling study of isolated compounds and their analogs targeting
all enzymes involve in citric acid cycle was conducted to examine potential binding
affinity of these compounds toward proteins in citric acid cycle. Docking study showed
analogs S-2-aminosuccininamide (AN21), levulinic acid and isolated compound SAA4
exhibiting high affinity binding to the fumarase enzyme that plays an important role in
citric acid cycle. Docking study clearly suggest compound SAA4 has potential inhibition
of gluconeogenesis. In conclusion, this study authenticated that C. rotundifolia potential
antidiabetic activity through inhibition of intestinal α-glucosidase, induction of glucose
uptake activity and possible inhibition of gluconeogenesis.
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CHAPTER ONE: GENERAL INTRODUCTION AND BACKGROUND

1.1

Natural products

1.1.1 Natural product overview
Plants produce different types of metabolites (primary and secondary) which
regulate multiple functions.1 Primary metabolites are synthesized by plants to maintain
biochemical processes such as growth and development. Primary metabolites include
amino acids, simple sugars, nucleic acids, and lipids. On the other hand, secondary
metabolites are chemicals synthesized by plants to perform specific functions that are not
necessary for biochemical processes. Alkaloid, terpenoid and phenolics are the major
groups of compounds in plants (figure 1). Secondary metabolites are chemicals
synthesized by living organisms to perform certain functions that are not specifically for
biochemical processes; for example, defenses against herbivory or pollinator attraction. 2
Natural products are defined as organic compounds originating from living organisms
such as animals, plants and microorganisms.3 However, the term "natural products" is
established from secondary metabolites.3 According to the definition mentioned
previously, natural products refers to whole organisms such as plants; animals; parts of
organisms like leaves, roots or flowers; extracts from organisms; isolated animal organs;
or pure compounds isolated from organism extracts such as flavonoid, terpenoid, alkaloid
or steroid.3
1.1.2

Natural product history as source of novel medicine
Plants are always very rich sources of drugs, and the majority of currently

available drugs on the market have been derived—directly or indirectly—from plants.4, 5

2
In fact, plants have actually provided a starting point for the synthesis of over 50% of
available used pharmaceutical drugs.6 For example, Glucophage® (metformin), one of
the cheapest and most popular oral hypoglycemic drugs available nowadays on the
market, is derived from Galega Officinalis (Fabaceae).3 Based on ethno-botanical data,
about 800 plant species show hypoglycemic activity and more than 1,000 plants
worldwide have been used as folk medicine to control of type-II diabetes.7 Momordica
charantia, commonly known as bitter melon, is one of the most common plants used to
treat diabetes in the world, particularly in Asia, South America and India. Folk medicine
of various native communities has long used medicinal plants to treat diabetes.
Examining this practice provides a new area of research on the antidiabetic effect of
medicinal plants.8 Natural products, especially medicinal plants, have played a very
important role in treating human disease, and the use of medicinal plants has been dated
back to ancient times.3 Natural products are used in the treatment of numerous health
conditions. Further, the use of natural products for medicinal purposes by countries such
as India, China and South Africa has been practiced for thousands of years.3 According to
the World Health Organization (WHO), 65% of the global population is dependent on
natural products for healthcare.3 In China, for example, more than 7,295 plant species are
used as sources of medicinal agents.3 Today, in developed countries, 70% to 80% of the
population uses some form of alternative or complementary medicine.3 Moreover, herbal
medicine is one of the most popular forms of traditional medicine in addition to being
ranked as the most lucrative industry in the international marketplace.3 Various cultures
worldwide still rely on herbal medicines with approximately 38% of American adults
using alternative medicines.9 People depend on alternative or complementary medicine

3
primarily to manage side effects of pharmaceutical drugs or turn to it as an alternative
when pharmaceutical options do not provide relief from disease. The drug discovery field
depends on natural products for new medicines especially because existing therapies have
many side effects that result in the recall of drugs.10 Therefore, there is a need to study
these medicinal plants in order to give scientific authentication to the proper use of these
plants and remove any medications that may cause harm to patients. It is encouraging to
see that, recently, many researchers became interested in giving scientific authentication
to the activity of plants used in traditional medicine around the world.
1.1.3 Sources of natural products
Sources of natural products are numerous and may include plants, marines,
animals and microbes. Plants are the richest source of natural products, and the use of
certain plants can be seen in herbal medicine throughout human history.6 The current
predicted number of plant species worldwide is around 250,0000.11 However, a limited
number of these plant species have been screened for medicinal properties. In fact, less
than 10% of medicinal plant species have been investigated and validated for their
medical properties.12 Furthermore, un-investigated plants could be a major source in drug
discovery. Therefore, the search for effective, safe, affordable and convenient agents
from medicinal plants has continued to be an important area of investigation. Numerous
drugs currently available on the market have been derived from plants either directly or
indirectly.13, 14 Examples include the narcotic analgesic morphine from Papaver
somniferum, the anticancer drug vincristine from Vinca rosea, the antimalarial drug
artemisinin from Artemisia annua, the anticancer drug Taxol from Taxus brevifolia, the

4
antibiotic penicillin from Penicillium ssp and the most common antidiabetic available
drug Metformin derived from Galega officinalis plant.3, 14 (Figure 1-1)

Figure 1-1: Structure of some important plant-derived drugs.
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1.1.4

Drug discovery from natural product
Compounds isolated from natural products have a significant role in the discovery

and developments of new medicines.7 In spite of combinatorial chemistry’s proposals of
new drugs, natural products still remain the main sources of drug discovery and are
involved in the most used clinical drug available today.8 According to a study of all new
chemical entities (1,355 total) accepted as new medicines in the period time between
January 1981 and December 2010, 26% are natural products or their derivatives, and
another 24% are synthetic natural product mimics or have natural product
pharmacophores. Also, 15% are biological macromolecules such as peptides, 6% are
vaccines and 29% are totally synthetic (Figure 1-2). 15 These data obviously prove that, as
a minimum, 50% of all these new drugs are related to natural products. In 1999, one of
the top twenty best-selling, non-protein medicines (simvastatin, pravastatin, lovastatin,
augmentin, enalapril, atorvastatin, ciprofloxacin, cyclosporine clarithromycin and) were
originally natural products or their synthetic derivatives, with expected sales exceeding
$16 billion annually.16 In addition to the important of natural products as sources of drug
leads and the significant role of natural products in drug discoveries, natural products
have greater chemical novelty and large-scale structural diversity than any other drug
sources.16
About 40% of the natural products recorded in the natural products database
(Dictionary of Natural Products, Chapman & Hall) are not derived from synthetic
chemistry.16 On the other hand, a variety of tools have been established to accelerate the
drug discovery process. Among the most popular and frequently used tools in drug
discovery are bioassay-guided fractionation and computer-aided drug design.
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Figure 1-2: Natural products as sources of new drugs over 30 years (1981 to 2010) Reprinted
from 17.

1.1.4.1 Bioassay-guided fractionation
The bioassay-guided fractionation method is frequently used in drug discovery
involving natural products because of its ability to connect the chemical profile of
extracts and fractions to specific biological tests.18 Bioassay-guided fractionation is a
process of generating a fractionated and refractionated extract using several analytical
methods until a pure biologically active compound is isolated.19 This technique begins

7
with fractionating the crude mixture into several fractions, then each fraction is estimated
using different bioassay systems. Only biologically active fractions are exposed to a
further fractionation process. The process of fractionation and biological assessment
continues until a pure biologically active compound is isolated.3 The general steps of
bioassay-guided fractionation are presented in Figure 1-3.

Figure 1-3: The general steps of bioassay-guided fraction.3

1.1.4.2 Computer-aided drug design
Connecting computational power and progressive technologies to combined
chemical and biological fields has extremely accelerated drug discovery, design,
development and optimization.20 Computer Aided Drug Design (CADD) is an approach
that plays an essential role in drug discovery and has increasingly become widespread in
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the pharmaceutical industry.20 Practically, Computer Aided Drug Design (CADD) refers
to diverse terms like computational drug design, computer–aided molecular design
(CAMD), rational drug design, computer–aided rational drug design, computer–aided
molecular modeling (CAMM) and in silico drug design.20 Computer Aided Drug Design
(CADD) is generally expressed using computational tools and resources for the storage,
management, analysis and modeling of compounds.20 The fundamental goal of CADD “is
to discover hits (active drug molecules), determine leads (the most likely candidates for
further evaluation), and modify leads i.e. transform biologically active molecules into
suitable drugs by improving their properties such as physicochemical, pharmaceutical,
ADMET/PK (pharmacokinetic) properties.”20 Several computational tools are used in the
computer-aided drug design process; these include ligand and structure-based
pharmacophore modeling, homology modeling, docking and scoring, ligand-based
quantitative structural activity relationship development, molecular dynamics simulation,
similarity-diversity analyses, designing and enumerating virtual libraries, virtual highthroughput screening and computational prediction of absorption, distribution,
metabolism, elimination (ADME) properties.21 There are two types of CADD approaches
based on the availability of the experimental 3D structures of the target proteins. The
ligand-based drug design approach, such as pharmacophore analysis and Quantitative
Structure Activity Relationship (QSAR), can be used when protein structures are
unknown. Otherwise, the structure-based approaches, for example molecular docking,
can be utilized when protein structures are known.17
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1.1.4.2.1 Molecular docking
Molecular docking is the most commonly used strategy in the structure-based
drug design approach. It is also used in the drug discovery method to find the highest
matches between a receptor and a ligand.17 The molecular docking process involves
predicting the conformations and orientation of a compound in the active site of target
macromolecules and detecting the preferred configurations and conformations of
molecules interacting therein.17 The major objectives of molecular docking are to perfect
structural modeling and make a suitable prediction of activity.3 Furthermore, molecular
docking has been used in different stages of the drug discovery pipeline, such as
quantitative structure activity relationship, virtual combinatorial library generation, lead
optimization and the discovery of a potential lead through virtual screening.22 In addition,
the application of molecular molding has been used to study of the physico-chemical
parameters of the ligand, involving absorption, distribution, metabolism and
elimination/toxicity using different applications and programs.20 In molecular modeling,
the scoring function is commonly used to determine the interaction between the ligands
and the binding sites of target macromolecules. For example, using one of the scoring
methods employed in virtual high throughput screening, a virtual library of a significant
number of ligands docked into the binding sites of target macromolecules is created,
which are then scored based on their affinity to the binding sites of the target
macromolecules.21 There are large numbers of docking programs that have been
developed and are used in the drug discovery process, including AutoDock, DOCK,
ArgusDock and FTDock.21 OpenEye Software sets (Fast Rigid Exhaustive Docking
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(FRED), make Receptor, Omega, FRED and VIDA) were used to run the molecular
docking studies.

1.2

Saudi flora
Saudi Arabia is a Middle Eastern country with a population of more than 25 million

people. In Saudi Arabia, people live in both urban and rural areas and quit sectors are still
use traditional natural medicine for health care and treatment of diseases.23 Saudi Arabia
has biodiversity, which consists of an admixture of elements from a variety regions like
Asia, Africa and the Mediterranean. The mountainous area of southwestern Saudi Arabia
is characterized by the richness of its flora and its species diversity.24 This region, from
Taif to the Yemen border, contains about 70% of Saudi flora. The southwestern part of
Saudi Arabia has the largest number of these medicinal plants spread in area named
Alsawdah mountain near the city of Abha, the capital of Asir province.4 The climate in
this region differs from all other regions of Saudi Arabia due to the heavy rainfall and
high altitude.4 The climate around the Abha area is characterized by differences in
temperature and relatively high rainfall throughout the year coupled with complex
topography, resulting in the construction of unique and diverse plant communities.21
Saudi flora contains 2,250 species arranged in 142 families; among these, more
than 1,200 species are expected to have medicinal uses.25 However, a limited number of
these plant species in this rich flora area have been screened for medicinal properties.
1.3

Vitaceae family
Plants of the grape family, the Vitaceae family, are identified by their climbing

vines and tendrils and the distinctive clusters of berries.26 The leaves are represented
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alternate, forming opposite from the tendrils and flowers. Flowers are regular with 4 or 5
small sepals.27 There are 4 or 5 petals, which may be united at the tips, falling away as
the flower opens with4 or 5 stamens. The ovary is positioned superior and consists of 2
(rarely 3 to 6) united carpels (syncarpous) with the partition walls present to form an
equal number of chambers.26, 27 It matures as a berry with 1 to 2 seeds per cell. Most
members of the Grape family have edible leaves, stems, sap, and berries. The vegetation
is often mildly astringent.27
1.3.1 Genus
The Cissus genus contains about 350 species; some of these species are used in
herbal medicine as treatment or supplement for different ailments. For example, Bush
Medicine Practitioners in Australia use C. hypoglauca as medicine for sore throat.28 In
Asia, many cultures use local species of Cissus to treat different aliments. In China, C.
assamica, is often used as an anti-snake venom as a result of decreasing endothelin-1 and
sarafotoxin 6B,29 while in India and Sir Lanka, a species called Cissus quadrangularis is
used for wound healing30 and as agent with anti-obesity activity.31 C. hamaderohensis is
used in West Asia, it is reported to inhibit the angiotensin converting enzyme (ACE),
aminopeptidase N (APN) and neutral endopeptidase (NGP).32 In Africa, several countries
use species of Cissus in their herbal medicine; for example, in Cameroon, they use C.
aralioides as an antimicrobial agent.33 Cissus rotundifolia is one of the known species in
Africa and Asia. It shows anti-bacterial properties as a crude methanolic extract;
however, it has not been investigated to identify the active constituent compounds. The
methanolic extracts of cissus rotundifolia were screened for their antibacterial activity
against different kind of bacteria such as against Bacillus cereus, Staphylococcus aureus,
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Listeria monocytogenes, Escherichia coli.34,35 C. rotundifolia is one of the common plant
species growing in southwestern Saudi Arabia and is used locally to treat different
aliments in traditional medicine such as skin disease , burns and to control the high blood
glucose in diabetic patient. Based on the efficiency of cissus rotundifolia in traditionally
uses, Investigation of the antidiabetic activity of C. rotundifolia might lead to a new
effective and safe antidiabetic agent so I focused this study on C. rotundifolia to
determine the plant compounds that have potential antidiabetic activity.

1.3.2 Cissus rotundifolia
Cissus rotundifolia is a perennial, climber, evergreen wild plant belonging to the
family of Vitaceae (grape family).36 It is known as a common Arabian wax cissus, Peruvian Grape Ivy, Venezuelan tree bine and, locally (in south of Saudi Arabia), as
Algalaf.37 It is commonly used as a food thickener. Moreover, it was found to have many
therapeutic effects such as hypoglycemic and hypolipidemic as an extract however it has
not been investigated for specific active compound.34, 38 In addition, its extract shows
antibacterial activity.35 Cissus rotundifolia grows extensively in the southern part of
Saudi Arabia, and its leaves are widely consumed after cooking as leafy vegetables. It is
commonly used to prepare various dishes according to the traditional dietary culture of
locals and used as alternative medicine to reduce the blood glucose for diabetic patients
and skin burns.37 However, it has not been studied for its antidiabetic activity. Therefore,
this study aimed to evaluate the antidiabetic components of Cissus rotundifolia leaves.
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1.3.3 Morphology

Figure 1-3 : Cissus rotundifolia (Arabian wax cissus, grape ivy)

The Cissu rotundifolia plant is a strong climber up to 30 ft long. Stems are often
4-5 feet sloping and soft of hairless.27 Tendrils are 2-fid. C. Rotundifolia leaves are
simple and sometimes lobed. Leaf-stalks are soft, up to 1 cm long and up to 8 x 8 cm in a
circular to ovate shape, blunt at the tip, heart-shaped at the base with a toothed margin,
velvety to hairless on both sides, thick and fleshy.27 Stipules are up to 4 mm long,
semicircular, and hairless. The flowers are borne in lax cymes, leaf-alternated and at
branch ends.36 Cymes are carried on 3 cm long stalks and flower-stalks are 4-5 mm and
flower-buds are 3.5 x 1.5 mm.36 Petals are green and the ovary hairless with a length of
0.5 mm. Fruit is 1.5 x 1.3 cm and red when ripe. Seeds are 1-2 per fruit, 9 mm. long, and
smooth with a single crest.27, 36 Cissus rotundifolia is native to Africa and the Arabian
Peninsula.37
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1.3.4 Taxonomy
The generic name originated from the Greek word kissos, meaning "ivy."39 In the
1980s, the genus was divided according to certain details of the flower. The large
caudiciform species were changed to the new genus Cyphostemma. The genus name was
started by Car Linnaeus who used species epithets that are adjectives with the feminine
grammatical gender in Latin (e.g., C. trifoliata L.). This matches the form of tree names
ending in -us in Latin and having feminine gender.40 The Cissus rotundifolia plant
belongs to one of the biggest kingdoms of plant called Plantae. The general taxonomy of
Cissu rotundifolia as shown in table 1.

Kingdom

Plantae– plantes, Planta, Vegetal, plants

Subkingdom

Viridiplantae – green plants

Infrakingdom

Streptophyta – land plants

Super division

Embryophyta

Division
Subdivision
Class

Tracheophyta – vascular plants, tracheophytes
Spermatophytina – spermatophytes, seed plants, phanérogames
Magnoliopsida

Superorder

Rosanae

Order

Vitales

Family

Vitaceae – grapes

Genus

Cissus L. – treebind, treebine

Species

Cissus rotundifolia (Forssk.) Vahl – Venezuelan treebine

Table 1-1: General taxonomy of Cissu rotundifolia.
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The species of Cissus genus are frequently used as medicinal plants as they
contain vitamins, proteins, polyphenols and carbohydrates. Leaves of Cissus genus
contain Sterols, Quinones, and Phenolic compounds. In addition to, Anthocyanins,
Saponins and flavonoids are found in the plants leaves and fruits.41 Phytochemical studies
on methanol extract has been reported the presence of triterpenes including α- and βamyrins, β-sitosterol, ketosteroids, phenols, tannins, carotene and vitamin C. 41
1.3.5 Occurrences of Cissus rotundifolia
Cissus rotundifolia is one of the most common plants that grow freely in the wild
with no agricultural treatments that allow this plant to be consumed as a food.37 This
species of plant is consumed worldwide in both developing and developed nations and
provides nutrition and food security for poor rural communities in several regions.42, 43
For example, C. rotundifolia serves as a diet supplement in Japan, Europe and North
American.44-46 The known plants of these species are rich in minerals, dietary fiber,
vitamins, amino acids and fatty acids.47, 48 Previous studies showed that the
corresponding domesticated types of these plants have some therapeutic potential; for
example, phytic acid has been shown to have anticancer and antioxidant activity.49, 50
Therefore, there are indeed reasons to investigate the nutritional impacts of this plant.
Moreover, it is necessary to understand its impacts on consumer’s health51.
1.3.6 Medical uses of Cissus Rotundifolia
Cissus rotundifolia (fam, Vitaceae) spread from the African Mediterranean region
and are currently cultivated in many countries worldwide.37 It was consumed by the
ancient Greeks, Romans and Persians and reached the Far East being used either as a
food or alternative medicinal as anti-inflammatory.26 In the southwestern part of Saudi
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Arabia, people use the leaves of cissus rotundifolia to control a variety of medical issues
like skin disease, burns, cold symptoms and, in traditional medicine for the patient who
suffers from diabetes to control the high level of glucose in the blood.37
1.4

Diabetes mellitus overview
Diabetes mellitus (DM) is a metabolic disease characterized by high levels of blood

glucose resulting from defects in insulin production or insulin action. The increase of the
diabetes rate world-wide is projected to reach pandemic levels over the next 10-20 years.
1.5

Classification of diabetes mellitus
In 1997, the American Diabetes Association (ADA) established new classification

criteria for diabetes mellitus disease.52 The ADA classified Diabetes in four clinical
classes: the first clinical class of diabetes is Type 1 diabetes (T1DM) based on β-cell
destruction leading to absolute insulin deficiency. The second class is the most common
type of diabetes; type 2 diabetes mellitus (T2DM) diagnosed due to a progressive insulin
secretory weakness on the background of insulin resistance. The third clinical class of
diabetes includes other specific types of diabetes resulting from other causes such as
genetic defects in insulin action, genetic defects in β-cell function and diseases of the
exocrine pancreas. The fourth class is Gestational diabetes mellitus (GDM) that occurs
under specific health conditions and is diagnosed during pregnancy.53
1.6

Clinical diagnosis of diabetes
Diabetes can be diagnosed through direct blood glucose level testing during

individuals primary clinical care with low-risk and diabetes risk assessment. Early
diagnosis of type 2 diabetes mellitus (T2DM) is recognized by blood tests that measure
plasma glucose levels (PG).52 The fasting plasma glucose level (FPG) is the most
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preferred test to detect the blood glucose level in the body with a level of ≥126 mg/dL or
7.0 mmol/L verified by doing the test again on another clinic visit. This test needs fasting
for at least 8 h. Another test is the 2-hour plasma glucose (PG) of ≥200 mg/dL or
11.1 mmol/L in a patient with frank symptoms of diabetes like polyuria, unexplained
weight loss and polydipsia.54 A positive result of the oral glucose tolerance test (OGTT)
will demonstrate a PG level of ≥200 mg/dL or 11.1 mmol/L after a glucose load
containing 75 g of glucose solution in water. Although the two-hour PG OGTT test is
more accurate, it is not commonly used in the clinic because of less convenience and
more expense for patients.
1.7

Clinical management of diabetes
The initial evaluation required for a patient suffering from a high blood glucose

level is specific to the patient’s risk factors and symptoms. Comprehensive care for a
patient to help to optimally manage the diabetic case or even diagnose prediabetes is
necessary. The main way to control diabetes proceeds from Non-pharmacological therapy
(e.g. lifestyle change) to using antidiabetic therapy followed by blood glucose
monitoring.
1.7.1 Non-pharmacological Management
1.7.1.1 Lifestyle Modification
Lifestyle modification is the most effective way to prevent one of the most
common type of diabetes (T2D) and leads to about a 58% reduction in risks over 3 years
.55 The patient suffering from one or two of high risk factors is highly recommended to
implement lifestyle changes such as healthy diet and more time exercising. Later, the
diabetic patient already suffering from diabetes, needs to follow up with nutrition
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specialists to follow the right diet that will help to avoid sugar sources that increase the
level of blood glucose. On the other hand, the patient diagnosed with diabetes needs to
moderate his/her weight loss (~ 7% of body weight) as one of the important tactics to
control diabetes and impact the cholesterol level in addition to positively controlling
blood pressure.55 Diabetic patient can manage weight loss with a balanced diet, avoiding
carbohydrates and control of the calories daily consumed.56, 57
Also, other studies show that exercise plays an important role in preventing and
controlling hyperglycemia (lower HbA1C level by 0.66%).57 Exercise is considered an
essential part in order to prevent and control both prediabetes and diabetes. The U.S.
Department of Health and Human Services recommends that adults ≥18 years of age need
to do at least 150 min/week of moderate exercise, such as walking for 15 to 20 min, or 75
min/week of intensity physical activity like running and aerobics over at least 3 days per
week to achieve the benefits.52, 54 For patients younger than 18 years old, the U.S.
Department of Health and Human services recommends 60 min of physical activity
daily.52
In addition to the lifestyle modifications mentioned previously, the diabetes
patient needs to moderate alcohol consumption, especially the patient suffering from any
another cardiovascular disease, such as hypertension, with diabetes. Also, consumption of
alcohol in a fasted state is considered life-threatening in that it can cause hypoglycemia
and coma. In general, diabetic patients need counseling and psychosocial support to
successfully fight the complication effects of diabetes.58
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1.7.2 Pharmacological Management
Diabetes mellitus is a chronic disease difficult to control but the management of
this disease emphasizes keeping the plasma glucose levels in the blood as close as
possible to a normal range with the support of glucose lowering medications, healthy
nutrition and exercise.52 Target goals depend on each patient and the optimal way to
control the diabetes is determined after consultation with a medical practitioner. The
treatment goal differs from young, adult and elderly to reach normoglycemia without
significant hypoglycemia. Hemoglobin A1c (HbA1c) is the shape of hemoglobin (a
blood pigment that carries oxygen) that binds to glucose. The HbA1c test is used to
screen patient glycaemia and the key element is patient education and understanding of
the disease and complications related to diabetes, such as cardiovascular disease.
Management of diabetes depends on the type of diabetes. In general, Type 1 diabetes
mellitus is produced by absence of insulin; therefore, insulin should be controlled in a
patient suffering with Type 1 diabetes. Type 2 diabetes is described by insulin resistance
and treatments include oral anti-diabetic medications.59, 60
1.7.2.1 Insulin Therapy
Insulin is used for treatment of diabetes mellitus Type 1 and includes management
of combined split-mixed injections. Moreover, insulin is used in acute diabetes
emergencies, for example diabetic ketoacidosis (DKA) and pregnancy. Also, insulin can
be used as a supplement in diabetes Type 2 in case oral therapy fails to control blood
glucose concentrations. The main adverse effect observed with insulin therapy is
hypoglycemia, which might lead to brain damage. Mostly, patients with chronic renal
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impairment needed less insulin, so regular control of blood glucose levels must be made
to minimize the risk of hypoglycemia.61
1.7.2.2 Oral antidiabetic
There are major classes of oral antidiabetic medications, including biguanides,
sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4)
inhibitors and α-glucosidase inhibitors. Diabetes diagnosis depends on the HbA1C test
result, if HbA1C level rises to 7.5% while on medication or if the initial HbA1C is ≥9%,
combination therapy with two oral agents, or with insulin, may be considered.61, 62
However, these medications have limitations regarding efficiency, side effects and patient
compliance.61
1.7.2.2.1 Biguanide
Biguanide and its derivatives are the most common and available treatment for
diabetes. The discovery of biguanide started from extraction of a plant called Galega
officinalis; this plant was found to have different components, such as guanidine,
galegine and biguanide, which showed potential antidiabetic activity through decreasing
blood glucose levels.63 Metformin is the most common, cheapest available and the firstline oral medicine for type 2 diabetes mellitus (T2DM). Metformin is a biguanide that
activates adenosine monophosphate-activated protein kinase in the liver, causing hepatic
uptake of glucose and inhibiting gluconeogenesis through complex effects on the
mitochondrial enzymes.63 Metformin is a small molecule synthesized based on the
pharmacophore of the natural product compound isolated called galegine from Galega
officinalis. Metformin is the first line drug of T2DM, and it reduces the risk of
complications and mortality rates in patients through decreasing hepatic glucose synthesis
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(gluconeogenesis) and sensitizing peripheral tissues to insulin.63 However, metformin has
side effects: a risk of hypoglycemia and low chances of weight gain. Metformin might
also cause vitamin B12 and folic acid deficiency.64 This needs to be monitored, especially
in elderly patients. Another potential problem resulting from the use of metformin is a
decrease in the drug’s efficiency as diabetes progresses. Metformin is highly effective
when there is enough insulin production; however, when diabetes reaches the state of
breakdown of β-cells and results in a type 1 phenotype, metformin loses its efficacy.61
1.7.2.2.2 Sulphonylureas
Sulphonylureas is a class of organic compounds used as oral antihyperglycemic
drugs. The mechanism of action of sulphonylurease occurs through binding to the
sulfonylurea receptor on the beta cell surface to indicate secretion of insulin from the
pancreatic beta cells. Sulphonylureas are classified into two main groups: first generation
and second generation. Second generation sulphonylureas are characterized by fewer side
effects and more effective action than the first generation. The duration of action is
shorter in the first generation compared to the second generation. Universally used first
generation drugs are tolazamide, acetohexamide, tolbutamide and chlorpropamide.
Examples of the most commonly used second generation drugs are glibenclamide,
glipizide, glimepiride and gliclazide. Sulphonylurease is used either as monotherapy or in
combination with other antihyperglycemic drugs. The major side effects of this class of
antidiabetic drugs are hypoglycemia and weight gain.54, 65
1.7.2.2.3 Thiazolidinediones (TZDs)
Thiazolidinediones (TZDs) are a class of antidiabetic drugs use by patients
suffering from type 2 diabetes (T2DM). Rosiglitazone and Pioglitazone are the most
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common TDZ drugs currently available. The mechanism of action of TDZs depends on
binding to the peroxisome proliferator activated receptor gamma (PPAR-γ), a kind of
nuclear regulatory protein located in fat, muscle and liver. TZDs are expected to increase
insulin sensitivity, decrease cellular resistance and improve glycaemic control based on
enough production of insulin by pancreatic beta cells. TZDs might be used either as
monotherapy or in arrangement with other oral antidiabetic medications. In fact, use of
this class of drugs (TZDs) has been reduced due to side effects, such as myocardial
infarction, angina fluid retention, heart failure, hypoglycemia and liver injury as indicated
by multiple retrospective studies.65, 66
1.7.2.2.4 α-glucosidase inhibitors
Alpha glucosidase inhibitors (AGIs) are one of the first line therapy classes of antidiabetic drugs. These oral antidiabetic medicines are enzyme inhibitors that do not affect
the pancreas during the mechanism of action. The mechanism of action of AGIs depends
on the delay of carbohydrate absorption in the gastrointestinal tract. In addition, AGIs
control postprandial hyperglycemia and provide cardiovascular benefit. Carbohydrates
are present as oligo — or poly — saccharides. Polysaccharides need to be broken down
to monosaccharides (glucose, fructose, galactose) for digestion. For example, starch is
one of the most common polysaccharides digested through the alpha glucosidase enzyme
that breaks starch (polysaccharides) down to monosaccharides. Acarbose inhibits alphaglucosidase enzyme, thus preventing absorption of starch from the brush border of the
intestine. Therefore, AGIs class of antidiabetic medicine, which delays intestinal
carbohydrate absorption, reduces postprandial glycaemia and helps manage diabetes.67
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1.8

Diabetic case statistics in Saudi Arabia
425 million people suffer from diabetes worldwide according to the World Health

Organization and more than 39 million people in the MENA region. Saudi Arabia is one
of the MENA region countries that has a high prevalence rate of diabetes disease. By
2045, the expected number of diabetic patients around the world will rise to 67 million.
There were 3.852.000 people suffering from diabetes in Saudi Arabia in 2017 while the
total adult population is about 20,770,000 people, so the prevalence of diabetes in adults
is approximately 18.5%.61
In Saudi Arabia, diabetic disease occurs as one of the major medical issues and
cardiovascular disease is considered the first leading cause of death. Saudi Arabia has the
highest prevalence rates of diabetics with the increase of diabetes cases in Saudi Arabia
affecting more than one fourth of the adult Saudi population.68 The dramatic increase in
the prevalence rate of diabetes is a result of rapid socioeconomic development, lifestyle
changes and a change in dietary patterns. Etiological factors that cause high blood glucose
level like obesity, dietary habits and lack of exercise also contribute.69
1.9

Cissus rotundifolia as potential therapy for different medical issues
Cissus Rotundifolia as a crude extract has been reported to possess biological

activities.70, 71 72 This section provides a summary of the potential antimalarial and
antidiabetic effects of cissus rotundifolia as an extract.
1.9.1 Antimalarial activity of cissus rotundifolia as a crude extract
Malaria is an infectious disease that remains associated with considerable
morbidity and mortality and economic impact on developing societies.70 According to the
World Health Organization (WHO), malaria is widespread in 91 countries, mostly in
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Africa, Asia and Latin America. Approximately 40% of the world’s population is at risk
and it will continue to be distributed widely, essentially due to the drug resistance
developed by Plasmodium falciparum.72 A study of medicinal plant assessment showed
the antimalarial activity of crude extracts of Cissus rotundifolia.70 The results confirm
that this plant, consumed in traditional medicine, has significant antimalaria activity in
vitro and verified its use in traditional medicine.72, 73 However, in vivo studies of this
medicinal plant need to be completed to determine toxicity of the active constituents,
pharmacokinetic properties and diffusion in different body sites in addition to side
effects.73
1.9.2 Antidiabetic activity of cissus rotundifolia as a crude extract
Cissus rotundifolia is a climbing or prostrate shrub found throughout Africa and the
Arabian Peninsula being used as food. C. rotundifolia leaves extract has shown antidiabetic as well as antiparasitic properties.34, 74 In Saudi Arabia, the boiled leaves of C.
rotundifolia are prepared with meals as an appetizer and also used as an antipyretic in the
treatment of malaria and dengue fever.71 The present study was designed to evaluate the
hypoglycemic activity of C. rotundifolia components using different pathways to control
glucose blood levels compared to the most common antidiabetic drugs like acarbose and
metformin.
1.10 Molecular target of diabetes mellitus
Diabetes mellitus known as high level of glucose in the blood. The two main
sources of glucose in the body comes from either degradation of complex carbohydrates
or the producing of the glucose by liver as result of gluconeogenesis process. In order to
control of blood glucose level in early stage need to delay the absorption of glucose to the
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blood through inhibition Alpha-glucosidase enzyme as a molecular target that used to
breakdown the carbohydrate consumed to glucose. Moreover, through reduce the
production of glucose in the body that result from gluconeogenesis process.
1.10.1 Alpha-glucosidase (AG) enzyme
Alpha-glucosidase enzyme is located in the brush border in the small intestine,
which is the key enzyme in carbohydrate synthesis and breakdown.75 Alpha-glucosidase
is an exo-type carbohydrase, breaking glycosidic bonds in complex polysaccharides to
release absorbable monosaccharides (Fig. 1-4).76 The degradation of dietary
carbohydrates is considered the principal source of increased levels of glucose in the
blood. After hydrolysis of the complex dietary carbohydrate, the consequent absorption
in the intestine is made by alpha-glucosidases.77 One of the main strategies to control
type 2 Diabetes mellitus (T2D) is to decrease postprandial high blood glucose levels by
delaying the absorption of glucose through inhibition of carbohydrate-hydrolyzing
enzymes, alpha-glucosidase, in the digestive processes.78 Furthermore, one interesting
property of the alpha-glucosidase inhibitor is its ability to both improve and extend
glucagon-like peptide 1 (GLP-1) secretion in normal individuals and patients with Type 2
diabetes mellitus disease.79, 80
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Figure 1-4: Mechanism of action for alpha-glucosidase enzyme.81
1.10.2 Gluconeogenesis Inhibition
Gluconeogenesis is the main pathway to produce glucose in human body. In
diabetic patients, gluconeogenesis is high so the current target to control diabetic disease
is to inhibit gluconeogenesis in order to manage hyperglycemia. Gluconeogenesis is the
reversal of glycolysis, with some workarounds for the irreversible reactions in this
pathway.82 The reactions that interact for glycolysis and gluconeogenesis are presented in
blue in the figure 2-1, whereas gluconeogenesis’s reactions are shown in red.83 It is
realized that both pyruvate and oxaloacetate as substrates from the citric acid cycle are
starting points for gluconeogenesis. These pathways are presented here by green arrows.
The major substrate source for gluconeogenesis is protein, both dietary and endogenous.
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Moreover, any of the TCA cycle intermediates can serve as substrates for
gluconeogenesis.
Gluconeogenesis occurs only in the liver and the kidneys, and the liver is
synthesizing most of the glucose. Gluconeogenesis provides stable blood glucose levels
between meals; however, it is found to be high in diabetic patients. Gluconeogenesis also
helps us to maintain glucose levels when on a diet that is low in carbohydrates.83
Therefore, based on the similarity in the chemical structure between the isolated
compound from cissus rotundifolia and citric acid cycle substrates, our hypothesis builds
on the investigation of the binding affinity of isolated compound and citric acid cycle
enzymes in order to screen the inhibition activity for gluconeogenesis to control the
hyperglycemia.
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Figure 1-5: Gluconeogenesis process (in red) starts by oxaloacetate substrate from citric acid
cycle reactions.

The citric acid cycle, or tricarboxylic acid cycle, has a fundamental role in the
gluconeogenesis process that is considered the main pathway of the hepatic production of
glucose. The citric acid cycle is a series of reactions in mitochondria that result from
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oxidization of the acetyl moiety of acetyl-CoA to CO2 and decreases coenzymes that are
reoxidized through the electron transport chain related to the formation of ATP. The
enzymes involving in citric acid cycle play important role in regulation of
gluconeogenesis through catalyzes each step of the cycle to form the substrates.
Oxaloacetate is a substrate of citric acid cycle and it is the starting material for
gluconeogenesis. Although the properties of citric acid cycle enzymes have been studied,
the reports of targeted small molecule modulators of the activity have been limited.
Therefore, in this study the isolated compound and small analogs investigated for their
binding affinity to citric acid cycle enzymes that might lead to inhibition activity of
gluconeogenesis.

1.11 Project objectives
1. Extraction, isolation, and structural elucidation of the active constituents
from Cissus Rotundifolia with potential anti-diabetic activity using bioassayguided fractionation.
Cissus Rotundifolia (Vitaceae), which is locally called Algalaf, is
commonly used in Saudi folk medicine to control high blood glucose level
(Diabetes Mellitus). The overall objective of this study was the extraction,
isolation and structural elucidation of the active constituents with potential
antidiabetic activity from Cissus Rotundifolia using bioassay-guided fractionation.
The antidiabetic activities of the extracts, fractions and pure isolated compounds
obtained from the bioassay-guided fractionation were evaluated in vitro using
alpha glucosidase enzyme inhibition bioassay and glucose uptake induction to the
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cell using liver cell line (HepG2). The chemical structures of the pure isolated
compounds were elucidated using H NMR, C15 NMR and 2D NMR. To the best
of our knowledge, this is the first chemical profile investigation of the antidiabetic
activities in Cissus Rotundifolia.
2.

In-vitro evaluation of anti-diabetic activity of isolated compounds.
One of the current targets of novel antidiabetic agents to control high
blood glucose in the blood is glucose uptake induction. In fact, the most important
effects of insulin on glucose metabolism are the regulation of GLUT4 trafficking
and, consequently, glucose uptake.84 Moreover, glucose transport plays the
essential role in insulin-regulated glucose metabolism. The isolated compounds
with potential antidiabetic activity from cissus rotundifolia extract conduct an in
vitro evaluation of glucose uptake induction through glucose uptake assay.

3.

In-silico molecular modeling study of isolated compounds targeting citric
acid cycle enzymes.
Gluconeogenesis provides stable blood glucose levels between meals;
however, it is found high in diabetic patients. Gluconeogenesis also helps us to
maintain appropriate glucose levels when on a diet low in carbohydrates.
Therefore, based on the similarity in the chemical structure between the isolated
compound from cissus rotundifolia and citric acid cycle substrates, our hypothesis
builds on investigations of the binding affinity of the isolated compound and citric
acid cycle enzymes in order to screen the inhibition activity for gluconeogenesis
to control the hyperglycemia. Gluconeogenesis steps start by oxaloacetate, which
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is one of the citric acid cycle substrates. Therefore, gluconeogenesis could be
reduced through inhibition of citric acid cycle enzymes.
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2

CHAPTER TWO: ISOLATION OF ANTIDIABETIC CONSTITUENTS
FROM CISSUS ROTUNDIFOLIA THROUGH BIOASSAY – GUIDED
FRACTIONATION.

2.1

Introduction
Nature has long been the source of the basic elements of life such as food, medicine,

clothing and shelter.1 Natural products performed a significant role in human disease
therapy and compounds derived from natural products have continuously been noted as a
valued sources for drug discovery.1, 2
Plants are the richest source of remedies and the use of some plants is known in
herbal medicine throughout human history.3-5 The current predicted number of plant
species worldwide is around 250,000 species.6, 7 However, a limited number of these
plant species have been screened for medicinal properties. In fact, less than 10% of
medicinal plants species have been investigated and validated for their medical
activities.6 Plants have always been a very rich source for drug discovery, and the
majority of currently available drugs on the market have been derived directly or
indirectly from plants.6, 8 For example, several available drugs derived from plants for
different diseases therapy exist, such as the anticancer drug vincristine from Vinca rosea,
the narcotic analgesic morphine from Papaver somniferum, the antimalarial drug
artemisinin from Artemisia annua, the anticancer drug Taxol from Taxus brevifolia, the
antibiotic penicillin from Penicillium ssp 1 and the most common antidiabetic available
drug, Metformin, derived from Galega officinalis.9 10
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The Vitaceae is a commonly known plant family that forms one of the largest and
most diverse plant families worldwide, growing in a variety of environments. This family
contains more than 900 known species, occurs in 14 genera, and is mainly spread in
tropical and subtropical areas of the world.11 The largest genus of this family
is Cissus, including about 350 species. Some of the important genera belonging to the
Vitaceae family include Acareosperma, Ampelocissu, Cyphostemma, Amplopsis, Psedra,
Leea, Vitis and Cissus.4 Most of the plants in this family are identified by their climbing
vines, tendrils and distinctive clusters of berries. Their leaves are alternate, forming
opposite from the tendrils and flowers. Flowers are regular with 4 or 5 small sepals.12
Vitaceae is also considered one of the most economically important plant families due to
the cultivation of many edible Vitaceae species, including the European wine grape (V.
vinifera) and the North American fox grape (V. labrusca) which are the parent species of
most of the cultivated slipskin American grapes. The Boston ivy (q.v.; Parthenocissus
tricuspidata) and the Virginia creeper (q.v.; P. quinquefolia) are the most common
woody vines in the eastern United States.4, 13 The Vitaceae family has drawn the attention
of many researchers since their fruits, leaves and vegetables are traditionally consumed as
food and medicine to treat some skin burns in addition to uses as a diet supplement to
reduce the blood glucose level in diabetic patients .14 A number of plant species from the
Vitaceae family have been extensively reviewed in the literature for their medicinal
properties, such as Cissus quadrangularis, C. araloides, C. assamica, C.
hamaderohensis, C. hypoglauca, C. sicyoides, C. debilis, C. ibuensis, C. populne, C.
verticillata and C. rotundifolia screened as a crude extracts and showed that they have
medicinal activity as anti-inflammatory and anti-malaria, in addition to hypoglycemic
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activity as a methanolic extract however, it is not significantly investigate for the active
constituents compounds.11 Several parts of the plants, including the seeds, fruits and
leaves, of the Vitaceae family have been consumed by humans and reported to have
medicinal properties.11, 15
Cissus rotundifolia is a perennial, climber, evergreen, wild plant belonging to the
family of Vitaceae (grape family). It is known as a common Arabian wax cissus,
Peruvian Grape Ivy, Venezuelan tree bine and locally (in the south of Saudi Arabia) as
Algalaf. It is commonly used as a food thickener. Moreover, it was found to have many
therapeutic effects as a hypoglycemic and hypolipidemic , based on the literature study,
the hypoglycemic activities of plant extracts of C. rotundifolia still not fully investigated
to specific mechanism of action however the study mentioned that the antidiabetic
activity of C. rotundifolia extract could be due to the stimulation of insulin secretion from
the remaining β-cells which promotes tissue glucose utilization in diabetic rats either by
enhancing its uptake and metabolism or by inhibiting hepatic gluconeogenesis. Moreover,
C. rotundifolia extracts significantly corrected the levels of cholesterol and triglycerides
towards normal. This improvement may be partly attributed to the increase in insulin
secretion that affects lipid metabolism and to the regeneration of β-cell as a result of the
decrease in production of free radicals by lipid peroxidation.16 In addition, the methanolic
extract of cissus rotundifolia has been reported to possess antibacterial activity when
tested against E. coli, S. infantis, S. aureus and L. monocytogenes in study where only the
extracts of edible plants were screened for their antibacterial activity however the
investigation of specific active compound need future studies.17
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.18 Cissus rotundifolia grows extensively in the southern part of Saudi Arabia, and its
leaves are widely consumed after cooking as leafy vegetables. Cissus rotundifolia extract
has been reported to contain components such as flavonoid, hydrolysable tannin and
vitamin C. In addition to, an appreciable amount of protein, fat, crude fiber and minerals.
According to nutritional evaluation of cissus rotundifolia, the protein fraction includes a
relatively high level of essential amino acids; fat contains a high concentration of
unsaturated fatty acids; Macro elements (Magnesium, Sodium, Potassium; Microelements
(Iron, Zinc, Manganese, Copper and Chromium). However, up to present, no
phytochemical studies have been reported regarding the isolation and identification of the
phytoconstituents of C. rotundifolia. It is commonly prepared in various dishes according
to the traditional dietary culture of locals and is also used as an alternative medicine.
However, it has not been studied for its antidiabetic activity. Therefore, this study aims to
evaluate the antidiabetic components of Cissus rotundifolia leaves.
2.2

Distribution and uses of cissus rotundifolia plant in Saudi Arabia
Saudi Arabia is one of the Middle East countries with a population of more than

25 million people. In Saudi Arabia, people live in both urban and rural areas and sectors
still use traditional, natural medicine for health care and treatment of diseases.19 Saudi
Arabia has plant biodiversity, which consists of an admixture of elements from variety
regions like Asia, Africa, and the Mediterranean. The mountainous area of southwestern
Saudi Arabia is characterized by the richness of its flora and species diversity.20 Cissus
rotundifolia is a perennial, climber, evergreen wild plant belonging to the family of
Vitaceae (grape family).21 It is known as a common Arabian wax cissus, Peru-vian Grape
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Ivy, Venezuelan tree bine and, locally (in south of Saudi Arabia), as Algalaf.22 It is
commonly used as a food thickener. Cissus rotundifolia grows extensively in the
southern part of Saudi Arabia, and its leaves are widely consumed after cooking as leafy
vegetables. It is commonly used to prepare various dishes according to the traditional
dietary culture of locals and used as alternative medicine to treat some skin burns and
also uses to reduce the blood glucose for diabetic patients. However, it has not been
investigated for its antidiabetic activity. Therefore, this study aimed to evaluate the
antidiabetic components of Cissus rotundifolia leaves using the bioassay guided
separation of methanolic extract of C. rotundifolia leaves.

2.3

Aim of the study
Identification of the chemical constituents of the plants used in traditional

medicine is very important since several studies have found them to have potential
biological activities, such as potential antidiabetic activity.23 All established information
will expand our current knowledge of the ethnopharmacology of the plants that have
medicinal properties and are used in traditional medicine and might aid in identifying
new chemical entities with antidiabetic activities.23 The aim of the present study was the
extraction, isolation and structural elucidation of the active constituents with potential
anti-diabetic activity from Cissus rotundifolia using bioassay-guided fractionation. Cissus
rotundifolia (Figure 2-13) (Vitaceae), which is locally called Algalaf, is used in Saudi
traditional medicine for the treatment of skin burn, malaria and control of diabetes
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disease. Cissus rotundifolia grows widely in different regions close to Abha city, Saudi
Arabia.

2.4

Molecular target of diabetes mellitus
Diabetes mellitus known as high level of glucose in the blood. The two main

sources of glucose in the body comes from either degradation of complex carbohydrates
or the producing of the glucose by liver as result of gluconeogenesis process. In order to
control of blood glucose level in early stage need to delay the absorption of glucose to the
blood through inhibition Alpha-glucosidase enzyme which play an important role on
regulation of blood glucose level in the blood.
2.4.1 Alpha-glucosidase (AG) enzyme
Alpha-glucosidase is a carbohydrase enzyme, breaking glycosidic bonds in
complex polysaccharides to release absorbable monosaccharides (fig. 2-1).24 The
degradation of dietary carbohydrates is considered the principal source of increased
glucose in the blood. After the hydrolysis of the complex dietary carbohydrate, the
consequent absorption in the intestine is made by alpha-glucosidases.25 One of the main
strategies to control type 2 Diabetes mellitus (T2D) is to decrease postprandial high blood
glucose level by delaying the absorption of glucose through inhibition of carbohydratehydrolyzing enzymes, alpha-glucosidase, in the digestive processes.26
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Figure 2-1: Hydrolysis of Polysaccharides to glucose as catalyzed by alpha-glucosidase.
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2.5

Materials and methods

2.5.1 General procedures and reagents
1

H-NMR, 13C-NMR and 2D-NMR were conducted using Bruker AVANCE-400

MHz and 600 MHz NMR spectrometer in deuterated chloroform (CDCl3) using
tetramethylsilane (TMS) as the internal standard; chemical shifts are given in ä (ppm)
values. Column chromatography was carried out using silica gel (230–400 mesh)
purchased from Sorbent Technologies (Norcross, GA, USA). TLC was performed using
pre-coated silica gel PE Sheets purchased from Sorbent Technologies (Norcross, GA,
USA), visualized under ultraviolet at 254 nm, stained with Ceric Ammonium Molybdate
(CAM) stain and followed by heating. All solvents were obtained from commercial
suppliers and used as received.
α-Glucosidase enzyme (Cat. No. G 5003, Sigma Aldrich Chemical Co, USA).
Bovine serum albumin (Sigma Aldrich Chemical Co, USA), Sodium azide (Sigma
Aldrich Chemical Co, USA). Para nitrophenyl-α-d-glucopyranoside (Cat No: N 1377,
Sigma Aldrich Chemical Co, USA). Acarbose (Sigma Aldrich, PHR1253, USA).
2.5.2 Plant materials
Fresh leaves of Cissus rotundifolia were collected in June 2016 from the area near to
Abha, Saudi Arabia. Al-Sawdah Mountain, the site of Cissus rotundifolia plant
collection, is located east of Abha, in area between latitude 17°30’ north and 21°00’ north
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and longitude 41°30’ east and 44°30’. The plant was botanically authenticated, and a
voucher specimen was deposited in Pharmacognosy Department Herbarium, College of
Pharmacy, King Khaled University, Abha, Saudi Arabia.
2.5.3 Preparation of plant extracts and fractions
The leaves of Cissus rotundifolia (7 kg) were cut into small pieces and
homogenized in methanol (a blender was filled to third (1/3) volume with leaves, 1.5 L of
methanol was added, the mixture was homogenized for 5 min). Then, the mixture was
macerated in methanol for 72 hours. The methanol extract was filtered, concentrated
under reduced pressure at 40°C using a rotary evaporator and lyophilized to afford a
residue. The dried methanol extract (210 g) was dispersed in deionized water (500 ml)
and partitioned sequentially with n-hexane (500 ml×3) and ethyl acetate (500 ml×3).The
combined solvent of each partitioned extract was concentrated under reduced pressure at
40°C using the rotary evaporator and freeze dried for 72 hours to yield an n-hexane
fraction (32 g), an ethylacetate fraction (20 g) and the remainder of the water fraction
(158 g). All fractions were tested for their antidiabetic activity through evaluation of their
inhibition activity of α -glucosidase enzyme using α -glucosidase inhibition bioassay.

2.5.4 Isolation
According to the bioassay-guided fractionation, the ethyl acetate fraction showed
the greatest potential antidiabetic activity, thus this fraction was selected for further
study. The EtOAc fraction was subjected to column chromatography on silica gel (300 g)
and eluted with stepwise gradients of n-hexane/EtOAc (100:0, 90:10, 80:20, 70:30,
60:40, 50:50, 45:55, 40:60, 30:70, 20:80, 10:90, 0:100 v/v) and finally with 2 L methanol.
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A total number of 532 fractions (20mL each) were collected and combined on the basis
of their TLC profiles into five main fractions as follows: fraction I (70-136) (941 mg),
Fraction II (136-237) (633 mg), Fraction III (238-298) (460g), Fraction IV (299-363)
(302g) and Fraction V (362-534) (720 mg). All these sub-fractions are examined for α glucosidase inhibition bioassay in order to evaluate their antidiabetic activity through

inhibition activity of α -glucosidase enzyme.
2.5.5 Alpha-glucosidase inhibition assay
α-Glucosidase inhibitors act as competitive inhibitors of intestinal α-glucosidase
enzyme, which results in delay of the digestion and subsequent absorption of elevated
blood glucose levels.27 The extracts were pre-incubated with the α-glucosidase enzyme
before adding the substrate p-nitrophenyl- α-d-glucopyranoside (PNPG). The αglucosidase enzyme (Cat. No. G 5003, Sigma Aldrich Chemical Co, USA) was dissolved
at a concentration of 0.1 U/ml in 100 mM phosphate buffer, pH 7.0, containing bovine
serum albumin 2000 mg/ml (Sigma Aldrich Chemical Co, USA), and sodium azide 200
mg/ml (Sigma Aldrich Chemical Co, USA), which was used as enzyme source. Para
nitrophenyl-α-d-glucopyranoside (Cat No: N 1377, Sigma Aldrich Chemical Co, USA)
was used as substrate. Cissus rotundifolia extract was weighed and serial dilutions of 50,
25, and 12.50 mg/ml were made up with equal volumes of dimethylsulfoxide and
distilled water. Ten microliters of C. rotundifolia extract dilutions were incubated for 5
min with 50 µl of the α-glucosidase enzyme source. Then, 50 µl of substrate was added
and incubated for 5 min at room temperature. The pre-substrate and post substrate
addition absorbance was measured at 405 nm on a microplate reader (Biotek Instruments
Inc, USA). Percent α-glucosidase inhibition was calculated as follows: (1–B/A) Å~ 100,
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where (A) is the absorbance of control and, (B) is the absorbance of samples containing
extracts.
The activity of the α-glucosidase enzyme was measured by determining the color
developed by the release of p-nitrophenol resulting from the hydrolysis of substrate
PNPG by α – glucosidase using a spectrophotometric method. Experiments were done in
triplicate. Acarbose (Sigma Aldrich, PHR1253, USA) was dissolved in distilled water
and serial dilutions of 10, 5 and 2.5 mg/ml were made and used as positive controls.
2.6

Results and Discussion

2.6.1 Isolation and structure elucidation
The methanolic extract of the leaves of Cissus rotundifolia was dispersed in
deionized water and partitioned sequentially with n-hexane and ethyl acetate. Based on
the bioassay-guided fractionation, the ethyl acetate fraction showed the highest potential
antidiabetic activities and thus it was subjected to a series of chromatography techniques
to yield 6 compounds (Figure 2-12).
1

13

Compound 1 was isolated as a white powder, then identified using H, C and 2D
NMR spectra. 1H NMR spectrum showed signals mainly in the upfield region. The
spectra showed only two signals with sharp chemical shifts values; the first one
resonated in the olefinic region and the other was observed a little up field region. The
1H-NMR spectra of compound 1 also exhibited a signal corresponding to the proton
connected to C-3 hydroxyl group, which appeared as a multiplet at δ 3.46 (1H, m). Six
other proton signals were marked, including four secondary methyl groups (δH 0.91,
0.82, 0.81 and 0.79 all doublets with J = 6.6, 7.2, 6.4 and 6.4 Hz respectively) and two
tertiary methyl groups (δH 0.66 and 0.99. Since Cissus rotundifolia extract has been
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reported to contain components such as sterols. The olefinic signal at δ 5.28 (1H, J = 4.8
Hz) appeared to be characteristic of the sterols, and it was assigned to the H-6 proton in
the β–sitosterol (1) chemical skeleton. The 13C NMR spectra exhibited 29 carbon
signals characteristic of phytosterols: 13C NMR (151 MHz, CDCl3) δ 140.77, 121.74, 71.82,
56.78, 56.06, 50.14, 45.84, 42.34, 42.32, 39.79, 37.27, 36.52, 36.16, 33.95, 31.93, 31.92, 31.68,
29.72, 29.15, 28.27, 26.07, 24.32, 23.08, 21.10, 19.84,19.04, 18.79, 12.00, 11.88. In addition
to 2D, DEPT135 showed that 11 carbon signal inverted as represent of CH2 group: 13C
NMR (151 MHz, CDCl3) δ 121.75, 71.83, 56.78, 56.06, 50.13, 45.83, 42.31 (inverted),
39.78 (inverted), 37.26 (inverted), 36.16, 33.95 (inverted), 31.91,31.67 (inverted), 29.73
(inverted), 29.14, 28.27 (inverted), 26.06 (inverted), 24.32 (inverted), 23.07 (inverted), 21.98,
21.10 (inverted), 19.82, 19.42, 18.79, 12.00,11.88.. These data corresponded with the
structure of the β-sitosterol compound (Figure 2-2). The NMR data of compound 1 (βsitosterol ) is in agreement with the published values.28
Compound 2 was isolated as white powder. 1H NMR spectra of 2 showed one
methyl group signal at δ 3.72 (s, 3H) and a doublet signal at δ 2.84 (m, 1H) and 2.71 (d,
J=1.2Hz, 1H). Further, it showed a proton signal at δ 4.54- 4.62 (d, J = 2.5 Hz, 3H) with a
secondary alcoholic proton signal δ 2.09 (d, J = 49, 2.8 Hz, 1H). The 13C-NMR data of
compound 2 showed the presence of seven carbon signals in addition to two carbon
signals for acetone solvent at δ 30.03 and 202.07. The 13C-NMR data present two
carbonyl signal at δ 174.25, 171.98 and two peaks showed at the olefinic region at δ
110.23 and 145.33. One carboxylate methyl ester at δ 52.28.19 and C2 hydroxyl at 68.19
ppm respectively. One carbon signal at δ 39.36 which was assigned to methylene CH2
based on calculated NMR data and 2D NMR Dept 135 spectrum that showed signal at δ
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39.36 (inverted). Stereochemistry at C-2 could not be established at this point, further Xray analysis to establish the chirality at C-2 at this point could not be conducted. The
above data indicated that structure 2 was characterized as 1-methyl 4-vinyl 2hydroxysuccinate (Figure 2-2). The NMR data of compound 2 corresponds with the
published values. These dicarboxylic acids derivatives are widespread in nature and often
appear with other functional groups. In addition, several synthesized dicarboxylate have
wide spread applications in food industry and supplement preparations.29
Compound 3 was isolated as yellow powder. 1H NMR (600 MHz, CDCl3) spectra
of 3 showed two methyl group signals at δ 3.81 (s, 3H) and 3.71 (s, 3H) and a hydroxyl
group proton at δ 3.39 (s, 1H) with a doublet signal at δ 2.83 (ddd, J = 22.7, 16.4, 5.3 Hz,
2H) and secondary alcoholic proton signal at δ 4.53 – 4.50 (m, 1H). The 13C-NMR data
of compound 3 showed the presence of six carbon signals in addition to a carbon signal
for chloroform CDCl3. The 13C-NMR data presented two carbonyl signals at δ 173.74 and
171.03, and three oxy carbons signals at δ 67.24, 52.82 and 52.03 ppm, which correspond
to the dimethyl ester and C-2. One carbon signal, at δ 38.44, was assigned as C2 as result
of 2D NMR Dept 135 spectrum that showed signal at δ 38.44 (inverted). Stereochemistry
at C-2 could not be established at this point, further X-ray analysis to establish the
chirality at C-2 at this point could not be conducted. The above data indicated that
structure 3 was characterized as 1,4-dimethyl 2-hydroxybutanedioate (Figure 2-2). The
NMR data of compound 3 is in agreement with a cited literature value.30
Compound 4 was isolated as white crystal. 1H NMR (600 MHz, Acetone) spectra
of 4 showed carboxylic acid proton at δ 8.42 (s, 1H), and one methyl group signal at δ
3.71 (s, 3H) with a doublet signal at δ 2.76 (ddd, J = 23.4, 16.2, 5.9 Hz, 2H) and
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secondary alcoholic proton signal at δ 4.54 (dd, J = 7.2, 4.7 Hz, 1H). The 13C-NMR data
of compound 4 showed the presence of five carbon signals, in addition to two carbon
signals for acetone solvent. The 13C-NMR data presented two carbonyl signals at δ
174.39 and 172.68, and two carboxylate methyl signals showed at δ 68.29 and 52.58
ppm. One oxy-carbon signal at δ 39.36 which was assigned to C2 hydroxyl based on
calculated NMR data and 2D NMR Dept 135 spectrum that showed signal at δ 39.36
(inverted). Stereochemistry at C-2 could not be established at this point, further X-ray
analysis to establish the chirality at C-2 at this point could not be conducted. The above
data indicated that structure 4 was characterized as 3-hydroxy-4-methoxy-4-oxobutanoate
(Figure 2-2). The NMR data of compound 4 is in agreement with the published values.31
1

13

Compound 5 was isolated as a white powder, then identified using H, C and 2D
NMR. 1H NMR (600 MHz, CDCl3) spectra of 5 showed two proton signals at δ 7.88 (s,
1H) and 6.82 (s, 1H), assigned for C-1 and C-2. Then, a proton signal at δ 4.50 (d, 1H)
assigned for CHOH carbon proton and at δ 2.84 (m, 1H) proton assigned for hydroxyl
group proton. In addition, a signal proton showed at δ 3.74 (t, 3H) and δ 3.65 (m, 3H)
assigned for C-3 and C-5 as two methyl groups. Two signal peaks showed at δ 2.78 (m,
2H) and δ 2.70 (m, 2H) assigned for CH2 at C-6 and C-7. The 13C-NMR data of
Compound 5 presented twelve carbon signals. Two carbonyl signals at δ 173.78 and
171.15, and three methoxy carbons signal showed at δ 67.22, 52.42 and 52.12 ppm. One
oxy-carbon signal at δ 38.44 which was assigned to C2 hydroxyl based on calculated
NMR data and 2D NMR Dept 135 spectrum that showed signal at δ 39.36 (inverted).
Stereochemistry at C-2 could not be established at this point, further X-ray analysis to
establish the chirality at C-2 at this point could not be conducted. Two carbon peaks of 5
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spectra showed at δ 132.34 and δ 115.29 assigned for C-3 and C-4. The above data
indicated that structure 5 was characterized as Dimethyl-2-hydroxy-5methylenehexanedioate (Figure 2-2). The NMR data of compound 5 is in agreement with
a cited literature value.32
1

13

Compound 6 was isolated as a white powder, then identified using H, C and 2D
NMR. 1H NMR (600 MHz, CDCl3) spectra of 6 showed proton signals at δ 4.72 (s, 1H)
assigned for C-2 as and proton signal at δ 2.64 (m, 1H) assigned for hydroxyl group at C2. The 1H-NMR spectra of compound 6 also exhibited a signal corresponding to the
proton connected to C-3, which appeared as a multiplet at δ 2.66-2.54 (m, 2H). The 13C
NMR spectra of compound 6 exhibited 4 carbon signals δ 178.26, 175.55, 67.287 and
39.36. At δ 178.26, AT δ 175.55 showed two carbon signals assigned for carbonyl groups
at C-1 and C-4. Also, compound 6 spectra showed carbon peak at δ 67.287 and was
assigned for methoxy group at C-2. Stereochemistry at C-2 could not be established at
this point, further X-ray analysis to establish the chirality at C-2 at this point could not be
conducted. Carbon peak signal showed up filed at δ 39.36 and was assigned to CH2 at C3. The above data indicated that structure 5 was characterized as 2-hydroxysuccinic acid
(Figure 2-2). The NMR data of compound 6 is in agreement with the published values.33
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Figure 2-2: Isolated compounds (1-6) from Cissus extract
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2.6.2 Biological evaluation
α-Glucosidases are a series of enzymes located on the intestinal brush-border. The
source of important carbohydrates in diet (e.g. starch and sucrose) are hydrolyzed to
monosaccharide (glucose and fructose) by α-glucosidase, and then absorbed into the
blood to increase blood glucose level. Normally, these processes happen in the upper
portion of the small intestine and greatly increase blood glucose concentration, especially
in diabetic patients. 34 According to literature study proposed that α-Glucosidase
inhibitors (e.g. acarbose) increases the duration time of carbohydrate absorption and
flatten the blood-glucose concentrations. Therefore, acarbose have been used as the firstline drugs in treatment of diabetes.34 In this study, the aims were to explore the active
compound compared with acarbose and evaluate how this active compound inhibited αglucosidase activity. Hexane, ethyl acetate and aqueous extracts, cissus rotundifolia
showed variable inhibition of alpha-glucosidase enzyme based on alpha-glucosidase
inhibition assay. Alpha-glucosidase inhibition was measured in the concentration range
of 12.5 mg/mL to 50 mg/mL for each fraction and 12.5 uM to 100 uM for each pure
compound. As shown in figure 2-2, the ethyl acetate fraction exhibits significant
inhibition effects on alpha-glucosidase enzyme at different concentrations of 12.50, 25,
and 50 mg/mL, respectively, while the n- hexane fraction was found to have lowest
inhibition activity. The aqueous fraction showed slight inhibition activity against alphaglucosidase enzyme. In addition, the ethyl acetate fraction showed a concentrationdependent inhibitory effect on the alpha-glucosidase enzyme. These results obviously
suggest that the ethyl acetate fraction possesses the highest inhibition activity and led us

61
to carry out a study to identify the active constituents that may contain potential
antidiabetic compounds.
The ethyl acetate fraction subjected to column chromatography on silica gel to give
five main fractions (F1- F5). Fraction 1 afforded pure sitosterol compound 1 (Figure 212). Both fractions 3 and 4 demonstrated the highest inhibition activity in a
concentration-dependent manner. The bioassay guided purification of subfractions
resulted in the isolation and identification of six compounds: SAA1 (1), SAA2 (2), SAA3
(3), SAA4 (4), SAA5 (5) and SAA6 (6) (Figure 2-12). Compound 3 showed the most
promise with significant inhibition 51 % of alpha-glucosidase enzyme activity. The dosedependent manner present at four different concentration 100, 50, 25 and12.5 uM of the
promising compounds and acarbose was used as a positive control (figure 2-8).
In most reports, the mechanism of the inhibition against α-glucosidase was not yet
clear. 26 In our experiments, six compounds isolated from Cissus rotundifolia showed
different degree of activity against α-glucosidase.1,4-Dimethyl 2-hydroxybutanedioate
(3) and 3-hydroxy-4-methoxy-4-oxobutanoate (4) had promising inhibition activity, and
that might be because of C-2 hydroxyl group and dimethyl carboxylate at C-1 and C-4 in
compound 3 that also strengthen α-glucosidase inhibition activity. At the same time, from
compounds 2, 5 and 6’s structures, we inferred that if dimethyl group at C-1 and C-4
were changed, it might cut down α- glucosidase inhibition activity. The difference
inhibition activity between compound 2 and compound 3 could be related to the
structural difference at C-4 the vinyl ester). However, the increase of compound 3
inhibition activity could be attributed to the dicarboxylate methyl ester at C-1 and C-4. It
is worth mentioning that dimethyl ester is relatively non-polar and therefore the polarity
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difference between active and nonactive compounds could be the reasons of this
differences in the inhibition activity. The data from this study also indicated that 1,4dimethyl 2-hydroxybutanedioate (3), as the most effective compound, displayed a
significantly inhibitory activity against α-glucosidase. All the findings indicated that
cissus rotundifolia has potential activity for treatment of diabetes, and 1,4-dimethyl 2hydroxybutanedioate (3) as the most active compound showed inhibition of αglucosidase activity.

2.7

Conclusion
Cissus rotundifolia (Vitaceae), called Algalaf in Arabic, is used in Saudi folk

medicine for the treatment of skin, malaria and control of diabetes. The chemical
constituents were examined to determine chemical profile and potential antidiabetic
activity. In the present study, bioassay-guided fractionation and purification were used to
isolate the antidiabetic compounds of an extract of Cissus rotundifolia leaves. All
fractions, sub-fractions and pure compounds were screened for their antidiabetic activity
against the alpha-glucosidase enzyme. The highest inhibition activity was found to be in
the ethyl acetate fraction, resulting in the isolation of six compounds identified as
sitosterol (1), SAA2 (2), SAA3 (3), SAA4 (4) and SAA5 (5). Among the compounds
isolated and tested for the first time, SAA3 and SAA4 showed potent antidiabetic
activities through inhibition of the alpha-glucosidase enzyme different concentrations.
This finding may help us to identify new antidiabetic compounds as inhibitor of alphaglucosidase enzyme.
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Inhibitory activity for cissus rotundifolia fractions against alpha-glucosidase enzyme
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Figure 2-3 : Alpha-glucosidase enzyme inhibition of Cissus rotundifolia fractions

Inhibitory activity for ethyl acetate sub-fractions against alpha-glucosidase enzyme
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Figure 2-4: Ethyl acetate sub-fractions (1&2) at three different concentrations (10, 5, 2.5 mg/l), represented in blue,
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compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.
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Figure 2-5 : Ethyl acetate sub-fractions (3 & 4) at three different concentrations (10, 5, 2.5 mg/l), represented in blue,
compared with Acarbose as positive control, represent in orange, to show the inhibition of alpha-glucosidase enzyme
activity.
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Figure 2-6 : Ethyl acetate sub-fraction (5) at three different concentrations (10, 5, 2.5 mg/l), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.

65
Inhibitory activity for isolated compounds against alpha-glucosidase enzyme.

Figure 2-7 : Isolated compound (1) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.

Figure 2-8 : Isolated compound (2) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.
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Figure 2-9 : Isolated compound (3) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.

Figure 2-10 : Isolated compound (4) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.
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Figure 2-11 : Isolated compound (5) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.

Figure 2-12 : Isolated compound (6) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue,
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase
enzyme activity.
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Figure 2-13 : Photo of: Cissus Rotundifolia plant. (Vitaceae)
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3

CHAPTER THREE: IN-VITRO EVALUATION OF ANTI-DIABETIC
ACTIVITY OF ISOLATED COMPOUNDS.

3.1

Introduction
Diabetes mellitus is a metabolic disease characterized by high blood glucose level.

The major risk of diabetes is obvious based on the dramatically high distribution rate of
this disease. Recently, current estimations showed that the number of diabetics will
increase up to 439 million in 2030.1, 2The majority of diabetics, more than 90%, are type
2 diabetics.3 Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in the
hepatic and peripheral tissues. Glucose transporter 4 (GLUT4) plays a main role in the
pathophysiology of T2DM4. Generally, it is defective expression or translocation to the
peripheral cell plasma membrane in type 2 diabetes mellitus patients that delays the
entrance of glucose into the cell for energy production.5 Type 2 diabetes (T2DM) is
identified by insulin resistance and a progressive weakening in β-cell function.6, 7
Recently, it has been reported that insulin resistance is one of the most important factors
in the pathogenesis of type 2 diabetes, which is known not only by reduced
responsiveness of the peripheral target tissues like liver, skeletal muscle and adipose
tissue to insulin, but also by a remarkable decrease in glucose uptake and utilization.8, 9
Therefore, inducing glucose uptake in the above three key tissues is one of the main
effective therapeutic approaches for treating Type 2 diabetes.10 Meanwhile, natural
products are the main source of drug discovery.11
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Cissus rotundifolia (fam. Vitaceae) is one of the traditional medicinal plants widely
distributed in south western part of Saudi Arabia. C. rotundifolia leaves have been used
as a folk herbal drug to treat skin, bacterial infections, inflammatory conditions and flu in
alternative medicine.12, 13 It has also been reported to possess antibacterial activity when
tested against E. coli, S. infantis, S. aureus and L. monocytogenes in study where only the
extract of edible plant were screened for their antibacterial activity however the
investigation of specific active compound need future studies.14.15 Cissus Rotundifolia as
a crude extract has been reported to possess biological activities.16, 17,

18

For example,

antimalarial and anti-inflammatory effects as an extract.16, 19 However, there is no report
on the antidiabetic activity of C. Rotundifolia leaves antidiabetic activity such as glucose
uptake or metabolism. Therefore, this study was to investigate whether the leaves of C.
rotundifolia fractions possessed antidiabetic activity or not through inducing glucose
uptake.
3.2

Glucose uptake pathway
Through an intracellular pathway, insulin induces translocation of glucose

transporters (GLUTs) into the cell membrane of the cells.20-22 Actually, the most
important effects of insulin on glucose metabolism are the regulation of GLUT4
trafficking and, consequently, glucose uptake.23 Furthermore, glucose transport plays the
essential role in insulin-regulated glucose metabolism, including glycogen synthesis,
glycolysis and lipogenesis, where a dysfunction in this route in muscle and adipose tissue
signifies an important defect in the insulin action.24, 25 Insulin receptor is a heterotetramer,
involving two extracellular α subunits (binding fraction) and two transmembrane β
subunits (with intrinsic tyrosine kinase) linked by disulfide bonds.26 In insulin-responsive
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tissues, such as liver, skeletal muscle and adipose tissue, the action of insulin begins by
binding to its specific receptor.27 The activation of the insulin receptor makes a structural
change in the α subunit, leading to autophosphorylation of a tyrosine kinase domain of β
subunits and subsequent tyrosine phosphorylation of numerous protein intermediates,
involving insulin receptor substrate (IRS -1, 2, 3 and 4).28, 29 Both of these
phosphorylated substrates identify and bind to domains with homology SH2, especially
phosphatidylinositol-3-kinase (PI3-K).28, 30 Then, upon attachment to the cell surface,
protein kinase B (AKT) is activated, resulting in the AKT-dependent phosphorylation of
many substrates. In addition to glucose uptake, virtually all of insulin's metabolic effects
are regulated by AKT.31 For example, AKT-dependent phosphorylation of glycogen
synthase kinase 3 (GSK-3β) leads to the activation of glycogen synthase and enhances
glucose storage as glycogen.32, 33 Generally, the most important effects of insulin on
glucose metabolism are the regulation of GLUT4 trafficking and, consequently, glucose
uptake.23 Moreover, glucose transport plays the essential role in insulin-regulated glucose
metabolism. Therefore, the isolated compounds with potential antidiabetic activity from
cissus rotundifolia extract conduct to an in vitro evaluation of glucose uptake induction
through glucose uptake assay.

3.3

Aim of the study
Natural bioactive compounds have a long history of effective use in the treatment

of diabetes mellitus. Cissus rotundifolia (Vitaceae) have been used locally (in
southwestern part of Saudi Arabia), for the treatment of different ailments such as skin
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disease, malaria and hypoglycemia.34. Although the hypoglycemic effect of C.
rotundifolia leaves extract has been reported, the exact mechanism of this effect has not
been fully discovered. 19 In fact, the most important effects of insulin on glucose
metabolism are the regulation of GLUT4 trafficking and consequently glucose uptake.23
Moreover, glucose transport plays the essential role in insulin-regulated glucose
metabolism, including glycogen synthesis, glycolysis and lipogenesis. The present work
aims to study the effect of fractions and the isolated bioactive compounds of Cissus
rotundifolia extract on glucose uptake in liver cell lines (HepG2). This study evaluates
the glucose uptake activity of cissus rotundifolia leaves methanolic extract fractions, sub
fractions and the isolated compounds in HepG2 cell in vitro. The isolated compounds,
cell viability and antidiabetic activity of the extract were also discussed.
3.4

Materials and methods

3.4.1 Reagents
Dimethyl sulfoxide (DMSO), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium-bromide (MTT), sodium dodecyl sulphate (SDS). Fetal bovine serum (FBS)
was purchased from HyClone (Logan, UT, USA). Dulbecco’s modified Eagle medium
(DMEM), phosphate buffered saline (PBS) 1X solution and trypsin were purchased from
Gibco (Grand Island, NY, USA). Glucose (Oxidase) Liquid Reagents were purchased
from Fisher Scientific (Turnberry Hanover, IL, USA). Insulin solution from bovine
pancreas at 10 mg/mL insulin, pH 8.2, BioReagent, sterile-filtered, suitable for cell
culture was used as positive control.
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3.4.2 Extracts and Isolated Compounds
Fresh leaves of Cissus rotundifolia were collected in June 2016 from the area near
Abha, Saudi Arabia. The plant was botanically authenticated, and a voucher specimen
was deposited in Pharmacognosy Department Herbarium, College of Pharmacy, King
Khaled University, Abha, Saudi Arabia.
3.4.3 Preparation of plant extracts and fractions
The leaves of Cissus rotundifolia (7 kg) were cut into small pieces and
homogenized in methanol (a blender was filled to third (1/3) volume with leaves, 1.5 L of
methanol was added, and the mixture was homogenized for 5 min). Then, the mixture
was macerated in methanol for 72 hours. The methanol extract was filtered, concentrated
under reduced pressure at 40°C using a rotary evaporator and lyophilized to afford a
residue. The dried methanol extract (210 g) was dispersed in deionized water (500 ml)
and partitioned sequentially with n-hexane (500 ml×3) and ethyl acetate (500 ml×3).The
combined solvent of each partitioned extract was concentrated under reduced pressure at
40°C using the rotary evaporator and freeze dried for 72 hours to yield an n-hexane
fraction (32 g), an ethylacetate fraction (20 g) and the remainder of the water fraction
(158 g).
3.4.4 Cell Culture
A human cancer liver cell line (HepG2) was obtained from American Type Cell
Culture (ATCC, Rockville, MD, USA). The HepG2 cell line was maintained at 37°C in a
humidified atmosphere of 5% CO2 in a DMEM medium containing 10% fetal bovine
serum and antibiotics (100 IU/mL penicillin and 100 µg/ml).
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3.4.5 Cell viability assay
Cell viability was determined by the MTT method, as previously described, with a
modification. Briefly, cells (1 ×104cells/well) were seeded into a 96-well plate and
allowed to attach to the well overnight. Fractions were then added at different
concentrations (100, 50, 25, 12, 50 mg/ml) and cells were incubated for a further 24
hours. After incubation, 10 µL of 5 mg/mL of MTT dye was added to the cells for 4
hours at 37°C, followed by the addition of 100 µL of 10% SDS in 0.01 N HCl as a
solubilizing agent. The absorbance at 570 nm was recorded using an ELISA microplate
reader. The results of viability were expressed as a percentage of the control.
3.4.6 Glucose uptake assay
Glucose uptake using human liver cancer cell line (HepG2) as liver tissue plays a
significant role in controlling blood glucose level. Briefly, HepG2 cells were seeded in
96-well plate with some wells left blank. Then, when the cells gained confluence, the
medium was exchanged for DMEM containing 0.2% BSA and incubated for 18 hours.
After incubation, the cells were treated with DMEM containing 0.2% BSA with the
selected concentrations of test samples for another 24 h. Then 10 uL of medium was
removed from each well and placed into a new 96-well plate that contained 200 uL of
glucose oxidase reagent (Glucose CII-Test, IL, USA). Finally, the plate was incubated at
37C for 15 min and the optical density (OD) was measured at 490 nm using a microplate
reader. The percent of glucose uptake was estimated by subtracting the glucose
concentrations of the blank wells from the remaining glucose in the cell plated wells.
Insulin (10 mg/mL) was used as positive control.
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3.5

Results and Discussion

3.5.1 Cell viability assay
The cell viability of the methanol extract and the fractions of ethylacetate and hexane
from Cissus rotundifolia on HepG2 cells was assessed by MTT assay (Figure 3-1). At the
concentration of 100 mg/mL, the cell viability of the extract was about 85% for HepG2
and the cell viability of the ethylacetate fraction was evaluated at concentration 100, 50,
25, 12, 50 mg/ml respectively as presented in figure 3-1. Cissus rotundifolia extracts
toxicity was tested in vitro in HepG2 cell line using MTT assay. Extract concentrations
that kept at least 80% cell viability were considered as safe. MeOH extract (Fig. 3-1) was
found to be safe up to 100 mg/ml where’s hexane (Fig. 3-1) and aqueous extract (Fig. 31) were found to be lower than 80% cell viability at 100 mg/ml. Ethyl acetate extract
(Fig. 3-1) was found to be safe up to 100 mg/ml that showed 86% cell viability at 100
mg/ml. Accordingly, all the efficacy studies for the three extracts were performed at safe
concentrations. Therefore, different doses of the methanol extract and fractions from C.
rotundifolia leaves (12.5, 25, 50 and 100 mg/mL) were used in the following glucose
uptake experiments.

Cell Viability effect of Cissus rotundifolia on HepG2 cell line
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Figure 3-1 : Comparison of cell viability results obtained using MTT. Cells were treated with 12.5-100 mg/ml of each
fraction represent in (12.5 (blue), 25 (orange), 50 (gray), and 100 (yellow)). MTT assay was used to measure the cell
viability %..

3.5.2 Glucose uptake assay
The effect of methanol, ethylacetate and hexane extracts of C. rotundifolia leaves on
glucose uptake in HepG2 cells are illustrated in Figure 3-2. The ethylacetate fraction
showed a significant induction of glucose uptake in HepG2 cells with a value of 27% at
the concentration of 50 mg/mL compared with insulin as positive control. Insulin
increased glucose uptake in HepG2 cells of about 18%, while the hexane fraction showed
14 % inducing glucose uptake activity and the aqueous fraction showed 20 % induction
of glucose uptake activity in HepG2 cells. So, the result indicates that the ethylacetate
fraction has a promoting effect on HepG2 cells and the ethylacetate fraction has the most
promising induction of glucose uptake, represented in figure 3-2. Moreover, the present
study was conducted to evaluate the effect of six compounds were isolated from cissus
rotundifolia on glucose uptake activity in HepG2 cell line, and insulin used as positive
control. Furthermore, this study highlights potential anti-diabetic compounds in cissus
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rotundifolia. The results indicate that the isolated compounds 3-hydroxy-4-methoxy-4oxobutanoate (SAA4) and 1,4-dimethyl 2-hydroxybutanedioate (SAA3) have promising
glucose uptake inducing activity (Figure 3-4). 3-Hydroxy-4-methoxy-4-oxobutanoate
(SAA4) has the most significant induction of glucose uptake activity about 26% at 100
uM concentration. Additionally, isolated compound 1,4-dimethyl 2-hydroxybutanedioate
(SAA3) showed the enhancement in glucose uptake by 24% at 100 uM concentration.
While the rest compounds β-sitosterol (SAA1), dimethyl-2-hydroxy-5methylenehexanedioate (SAA5), and 2-hydroxysuccinic acid (SAA6) showed no effect
on glucose uptake inducing activity in comparison to control in HepG2 cell line (figure 37). Compound 4 was found to be most promising compound over the isolated compounds
for inducing glucose uptake in liver cell line. Generally, liver is major site of glycogen
storage and thus, glucose uptake activity is important to maintain normal blood glucose
level35. Present study showed that the isolated bioactive compounds SAA4 and SAA3
enhance the glucose uptake in HepG2 at dose dependent manner which may be due to its
effect on the receptors on the cell membrane in liver cell line (HepG2). Future in vivo
study to confirm our data is important to support the novel glucose uptake induction of
these compounds.
3.6

Conclusion

In the present study, bioassay-guided fractionation and purification were used to isolate
the antidiabetic compounds of an extract of Cissus rotundifolia leaves as mentioned in
Chapter2. All fractions, sub-fractions and pure compounds were screened for their
antidiabetic activity through glucose uptake inducing activity on the cell. The highest
inducing activity was found to be in the ethyl acetate fraction and two isolated c
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compounds SAA3 (3), SAA4 (4). Compounds SAA4 and SAA3 showed potential
antidiabetic activity through inhibition of glucose uptake in comparison to insulin. Future
investigation of antidiabetic activities of isolated compounds in vivo to elucidate the
mechanism could highlight the potential medicinal value of Cissus rotundifolia and
isolated compounds.

Effect of Cissus rotundifolia fractions on glucose uptake
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Figure 3-2 : Effect of Cissus rotundifolia fractions on glucose uptake. Fractions of Methanol, Ethylacetate, hexane and
aqueous represent in orange, compared with insulin as positive control represent in gray to show the induction of
glucose uptake activity.

Effect of isolated compounds from Cissus rotundifolia on glucose uptake
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Figure 3-3 : Isolated compound (1) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange,
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity.
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Figure 3-4 : Isolated compound (2) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange,
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity.
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Figure
3-5 : Isolated compound (3) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, compared
with insulin as positive control, represented in gray, to show the induction of glucose uptake activi
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Figure 3-6 : Isolated compound (4) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange,
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compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity..
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Figure 3-7 : Isolated compound (5) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange,
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity..

25.00
20.00
15.00
10.00
5.00
0.00
100

50

25

Concentration (µM)

Control

SA_6

12.5

insulin

Figure 3-8 : Isolated compound (6) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange,
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity.
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4

CHAPTER FOUR: IN-SILICO MOLECULAR MODELING STUDY OF
ISOLATED COMPOUNDS TARGETING CITRIC ACID CYCLE ENZYMES

4.1

Introduction
Glucose homeostasis is physiologically maintained by balance between glucose

production by liver and glucose consumption by the peripheral tissues.1 Hepatic glucose
production and glucose utilization is controlled by insulin, so, in non-insulin-dependent
diabetes mellitus (NIDDM), hepatic glucose production is high and demonstrates a
positive correlation with concentrations of glucose in plasma.2 Moreover, increases in
hepatic glucose production are considered the principal cause of fasting hyperglycemia in
NIDDM.3 In the liver, two processes produce glucose (gluconeogenesis and
glycogenolysis); however, gluconeogenesis develops to be significantly increased in
NIDDM.3 When the process of gluconeogenesis increases, it will further cause increased
hepatic glucose production and a positive correlation between the rates of
gluconeogenesis and fasting plasma glucose concentration has been discovered in
NIDDM subjects.4, 5Therefore, reduced hepatic glucose production also plays an
important role in controlling blood glucose level and is considered a new target for
antidiabetic research.6 Gluconeogenesis begins in the mitochondria through citric
acid cycle intermediates, starting throughout conversion to oxaloacetate, which can also
function as substrates for gluconeogenesis.7 Gluconeogenesis is a pathway involving a
couple of enzyme-catalyzed reactions.8 This pathway starts in the mitochondria or
cytoplasm based on the substrate being used.7 Gluconeogenesis begins with the formation
of oxaloacetate from carboxylation of pyruvate. This reaction needs one molecule of ATP
and it is catalyzed by an enzyme called pyruvate carboxylase.9 Pyruvate carboxylase is
stimulated by high levels of acetyl-CoA.10 Over the reaction of the citric acid cycle,
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Malate is the intermediate oxidized to oxaloacetate using NAD+ in the cytoplasm, where
other steps of gluconeogenesis show.11 Oxaloacetate is decarboxylated and
phosphorylated to generate phosphoenolpyruvate by phosphoenolpyruvate
carboxykinase.12
Gluconeogenesis provides stable blood glucose levels between meals; however, it
is found to be high in diabetic patients. Gluconeogenesis also helps maintain glucose
levels when on a diet low in carbohydrates.13 Therefore, based on the similarity in the
chemical structure between the isolated compounds from cissus rotundifolia and citric
acid cycle substrates, our hypothesis that molecular modeling to study binding affinity of
the isolated compound with citric acid cycle enzymes could reveal potential mechanism
of compounds isolated in our study to inhibit gluconeogenesis and control
hyperglycemia through inhibition of hepatic glucose production.

4.2

Citric acid cycle (Kreb’s Cycle)
The citric acid cycle, also called the Krebs or tricarboxylic acid cycle, is a series of

reactions in mitochondria that result from oxidization of the acetyl moiety of acetyl-CoA
to CO2 and decreases coenzymes that are reoxidized through the electron transport chain
related to the formation of ATP.14 The tricarboxylic acid cycle is a pathway for the
oxidation of carbohydrates, proteins and lipids because glucose, most amino acids and
fatty acids are metabolized to acetyl-CoA or intermediates of the cycle.15 The citric acid
cycle has a fundamental role in the gluconeogenesis process that is considered the main
pathway of the hepatic production of glucose. These processes occur in the liver tissues,
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the abnormally increased rate of hepatic gluconeogenesis contributes to hyperglycemia
in diabetes.13, 16
4.3

Steps of the citric acid cycle
Several steps during the citric acid cycle occur through enzymatically catalyzed

reaction in order to generate the molecules produced.17 The molecules produced from the
citric acid cycle, such as NADH, FADH, and ATP, are important as sources of energy,
while the intermediate produce through the citric acid cycle are important in another
process.18 For example, oxaloacetate is one of intermediates of the citric acid cycle that
plays an essential role and is the starting point of the gluconeogenesis process to produce
glucose.19 The steps of the citric acid cycle begin when acetyl CoA joins with
oxaloacetate, four carbon molecules, to form a six-carbon molecule (citrate). This step is
catalyzed by an enzyme called citrate synthase. The second step, which is a two-step
process, occurs when citrate is converted into its isomer, isocitrate. This step is catalyzed
by an aconitase enzyme and it involves the removal and then the addition of a water
molecule, which is the reason that the citric acid cycle is sometimes defined as having
nine steps rather than the eight. The third step, the enzyme isocitrate dehydrogenase
catalyzes this step when the isomer of citrate, isocitrate, is oxidized and releases a
molecule of carbon dioxide to form a five-carbon molecule called α-ketoglutarate. Next,
the fourth step begins when α-ketoglutarate oxidizes and releases a molecule of carbon
dioxide to form a four-carbon molecule. These four-carbon molecules pick up Coenzyme
A, producing the unstable compound succinyl CoA. The enzyme, α-ketoglutarate
dehydrogenase, is catalyzed in this forth step and also it is important in the regulation of
the citric acid cycle. In step five in citric acid cycle, the CoA of succinyl CoA is
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substituted by a phosphate group, then transferred to ADP to make ATP. The four-carbon
molecule produced in this step is called succinate. The enzyme that catalyzes this step is
the succinyl CoA synthetase enzyme. Then, in step six, succinate is oxidized, creating
another four-carbon molecule called fumarate. An enzyme called succinate
dehydrogenase catalyzes this step. The result of this reaction, two hydrogen atoms with
their electrons, are transferred to FAD, forming FADH2. The enzyme involved in this
step is implanted in the inner membrane of the mitochondrion, so FADH2 can transfer its
electrons directly into the electron transport chain. Step seven in citric acid cycle involves
the four-carbon molecule fumarate converting into another four-carbon molecule called
malate. The Fumarase enzyme catalyzes this step. The last step of the citric acid cycle,
step eight, creates oxaloacetate, a four-carbon compound formed by oxidation of the
malate molecule. Malate dehydrogenase catalyzes this step.
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Figure 4-1 : Citric acid cycle steps.
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4.4

Gluconeogenesis
Gluconeogenesis is a pathway to produce glucose in the human body.20 In diabetic

patients, gluconeogenesis is active, especially during fasting, so the current target to
control diabetic disease is to inhibit gluconeogenesis in order to manage hyperglycemia.21
Gluconeogenesis is a process to produce glucose from precursors such as lactate,
glycerol, pyruvate and amino acids.21, 22 A fasting condition requires synthesis of glucose
from non-carbohydrate sources. Most precursors must enter the citric acid cycle at some
point to be converted to oxaloacetate.3 Oxaloacetate is an intermediate of the citric acid
cycle that is the starting material for gluconeogenesis.23

Figure 4-2 : Citric acid cycle intermediate, Oxaloacetate, as starting material of Gluconeogenesis process
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The citric acid cycle, or tricarboxylic acid cycle, has a fundamental role in the
gluconeogenesis process that is considered the main pathway of the hepatic production of
glucose. The citric acid cycle is a series of reactions in mitochondria that result from
oxidization of the acetyl moiety of acetyl-CoA to CO2 and decreases coenzymes that are
reoxidized through the electron transport chain related to the formation of ATP. The
enzymes involving in citric acid cycle play important role in regulation of
gluconeogenesis through catalyzes each step of the cycle to form the substrates.
Oxaloacetate is a substrate of citric acid cycle and it is the starting material for
gluconeogenesis. Although the properties of citric acid cycle enzymes have been studied,
the reports of targeted small molecule modulators of the activity have been limited.
Therefore, in this study the isolated compound and small analogs investigation of their
binding affinity to citric acid cycle enzymes that might lead to a new discovery for
inhibition activity of gluconeogenesis.
.

4.5

Molecular docking
Molecular docking is a structure-based drug design approach. It is frequently used

in the drug discovery process to determine the best matches between a receptor/target
protein and a ligand/drug.24 The molecular docking method involves predicting the
conformations and orientations of a molecule in the active site of target macromolecules
and labeling the preferred configurations and conformations of molecules binding with
the active site of target macromolecules.24 The two major purposes of molecular docking
are right structural modeling and correct prediction of activity.25 Moreover, molecular
docking has been used in different phases of the drug discovery pipeline, such as
quantitative structure activity relationship, virtual combinatorial library generation, lead
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optimization and discovery of a potential lead through virtual screening.25 In addition, the
application of molecular molding has extended to the analysis of physico-chemical
parameters of the ligand, including absorption, distribution, metabolism and
elimination/toxicity using a variety of applications and programs.25, 26 Therefore, in this
present study, we use computational molecular modeling tools to study and predict the
interaction of isolated compounds from cissus rotundifolia extract analogs enriched with
functionalities with citric acid cycle enzymes and gluconeogenesis enzyme PEPCK.

4.6

Aim of the study

The promising isolated compounds from cissus rotundifolia identified as the dicarboxylic
aicds analogs showed similarity to malate structure (one of the main intermediates of
citric acid cycle). Therefore, the similarity in the chemical structure prompt us to build a
hypothesis for investigating the ability of the isolated compounds to inhibit the
gluconeogenesis process through inhibition of the citric acid cycle, one of the main
pathways to reduce the blood glucose level. The molecular docking process includes
predicting the conformations and orientations of a molecule in the active site of target
macromolecules and identifying the preferred configurations and conformations of
molecules interacting with the active site of target macromolecules. In this study, we used
molecular docking as one of the main strategies in the structure-based drug design
approach, so we use computational molecular modeling tools to study and predict the
interaction of the isolated compounds from cissus rotundifolia identified above.
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4.7

Materials and methods

4.7.1 Compounds
Six compounds were isolated from cissus rotundifolia as previously mentioned in
Chapter 2. In addition to, 2-aminosuccinicamide, 4-methoxy-2,4, dioxobutanic acid and
levulinic acid compounds. For docking, a vertical library of thirty analogs docked
including metformin as standard.

Figure 4-3: Chemical structure of Isolated compounds (1- 6) from Cissus rotundifolia extract.
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4.7.2 Molecular modeling
Molecular modeling was completed using four application softwares (make
receptor , Omega, Fred and Vida) using the method previously published by our group.27
4.7.3 2D and 3D Structures
A virtual library of thirty analogs and standard metformin compound, along with
known antidiabetic therapies for the treatment of diabetic mellitus, were prepared using
ChemOffice Ultra. The energies of the 3D structures were minimized using semiempirical PM3 calculations. The energy-minimized structures were then converted into
pdb files, maintaining all heavy atoms.
4.7.4 Generation of conformers
The energy-minimized structures were combined into a single continuous pdb file
to be used as an input for Omega. The Omega utility uses the MMFF94 force field to
form multiple conformations for each input ligand in the library in order to induce ligand
flexibility in an otherwise rigid model.
4.7.5 Receptor preparation
All of the citric acid cycle enzymes and phosphonyl pyruvate kinase enzyme were
prepared for the molecular docking process. Citrate synthase (PDB ID: 1cts), aconitase
(PDB ID: 7acn), isocitrate dehydrogenase (PDB ID: 3blw), alpha-ketoglutarate
dehydrogenase (PDB: 2jGD), succinyl CoA synthetase (PDB: 2FP4), succinate
dehydrogenase (PDB: 1neck), fumarase (PDB: 1fuo), malate dehydrogenase (PDB:
1MLD) and phosphonyl pyruvate kinase enzyme (PECK) (PDB ID: ) structures were
downloaded from the RCSB Protein Data Bank and prepared for modeling using Fast
Rigid Exhaustive Docking (FRED). The application allows for the creation of a grid box
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by the mode selection pane and adjustment of its size using the mode controls. The box
size would not exceed 50000–60000Å. Once the grid box size has been created, the
receptor is ready for use in the docking calculations.
4.7.6 Docking
Multiple scoring functions were used in order to identify a consensus structure and
score in the final output. The scoring functions involve Shapegauss, Chemgauss3,
Oechemscore, Screen score and PLP. Snapshots and visualizations of the chemical
interactions between the analogues and receptors were obtained using the VIDA
application.
4.8

Results and discussion

4.8.1 Molecular modeling
OpenEye Software sets (Fast Rigid Exhaustive Docking (FRED), make Receptor,
Omega, FRED and VIDA) were used to run the molecular docking studies.27 The crystal
structure of the citric acid cycle enzymes was used as a molecular target. A virtual library
of compounds was docked into a ligand binding domain of all the eight enzymes involved
in each step of the citric acid cycle in addition to phosphoenolpyruvate kinase protein
(PECK). The molecular docking results showed that analog 2-aminosuccininamide
(AN21), levulinic acid, and SAA4 compounds possess a high binding affinity on the
fumarase enzyme. Levulinic acid formed a hydrogen bonding interaction between the
carboxylic group at C-1 and the amino acid residue ASN135, in addition to another two
hydrogen bonding interactions between the oxygen of carbonyl group at C-4 with the
amino acid residues ASN141 and SER140 in fumarase (Figure 4.7). Meanwhile the
isolated compound, SAA4, is one of the top compounds that showed high binding affinity
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with the fumarase enzyme. The isolated compound SAA4 formed two hydrogen bonds
between the oxygen on the groups at C-1and C-3 with SER139 and ASN141, respectively
(Figure 4-8). Also, analog (AN21) exhibited a high binding affinity with no hydrogen
bonding interaction (Figure 4.9). Meanwhile, SAA3 compound, which is an isolated
compound from cissus rotundifolia, formed only one hydrogen bond interaction between
the carboxylic group at C-1 and the amino acid residue SER140 in fumarase (Figure
4.10). Alternatively, SAA4 and SAA3 compounds isolated from cissus rotundifolia
extract showed a binding affinity to three of the citric acid enzymes targeted: isocitrate
dehydrogenase, succinate dehydrogenase and succinyl CoA. The SAA4 isolated
compound showed the highest binding affinity to isocitrate dehydrogenase in comparison
to other isolated compounds and analogs. SAA4 formed hydrogen bonding interaction
between C-1 and the amino acid residue HIS301 (figure 4.12). SAA3 compound showed
a high binding affinity to the succinyl CoA enzyme forming two hydrogen bonding
between the hydroxy group C-2 and carboxylate oxygen C-1 with the amino acid residue
LYS172 and TYR173, respectively (figure 4.11). Meanwhile, analogs AN21 and
levulinic acid compounds showed a high binding affinity with the malate dehydrogenase
enzyme. The AN21 analog formed three hydrogen bond interactions between the amide
group at C-3 with the amino acid residue ASN118; in addition, two hydrogen bonds
appeared between the oxygen of carbonyl group at C-1 with two amino acid residues,
THR211 and ARG80, respectively (Figure 4.13). The isolated compound SAA3 showed
a high binding affinity to malate dehydrogenase, which exhibited a hydrogen bond
interaction to malate dehydrogenase enzyme between the hydroxyl group at C-2 with the
amino acid reside ALA223 (Figure 4.14). On the other hand, compound SAA2 showed
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less binding affinity on fumarase enzyme and show no hydrogen bond to malate
dehydrogenase. Structural differences between SAA3 and SAA2 are obvious reason for
different binding activities. SAA5 does not show binding affinity to fumarase enzyme.
Higher binding affinity of SAA3 could be attributed to its structural difference from other
compounds at C-1 and C-4. Furthermore, binding affinity study showed that C-2 hydroxy
group hydrogen bond to malate dehydrogenase enzyme is the key point behind higher
binding affinity to malate dehydrogenase enzyme. Phosphoenolpyruvate protein kinase
(PEPK) plays an important role in the gluconeogenesis process. The results of docking of
PEPK with the isolated compounds from cissus rotundifolia and analogs showed that
SAA3 possesses a high binding affinity. SAA3 formed hydrogen bonding interaction
between C-1 and the residue of the amino acids VAL335, SER286 and LYS290. (Figure
4.15). Generally, the result of the top twenty analogs showed a high binding affinity to
citric acid cycle enzymes and the phosphoenolpyruvate protein kinase. Analogs (AN21),
(AN4) and Levulinic acid, in addition to, the isolated compounds from cissus rotundifolia
(SAA4 and SAA3) showed the most promising binding affinity to more than one target of
enzymes that involved in citric acid cycle, so these molecules based on molecular
docking result need for further studied using biological evaluation in order to investigate
the antidiabetic activity through inhibition of gluconeogenesis using in vitro and in vivo
assays.

4.9

Conclusion
In this study, isolated compounds from cissus rotundifolia and their analogs,

including analogs with metformin like functionalities, were studied and their ability to
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bind to the citric acid cycle enzymes were analyzed using molecular modeling. The
molecular docking results showed that analog (AN21), levulinic acid and the isolated
compound SAA4 compounds possess a high binding affinity on the fumarase enzyme, In
addition to the isolated compound SAA3 and SAA4 showed high binding affinity on
malate dehydrogenase enzyme, suggesting that they may have potential for treating
diabetes mellitus through inhibition of citric acid cycle based on the high binding affinity
of these molecule to fumarase and malate dehydrogenase enzymes. More interestingly,
our molecular modeling and binding affinity results on the isolated compounds suggests
they may have inhibition activity for gluconeogenesis due to the high binding affinity to
citric acid cycle enzymes, in addition to the antidiabetic activity observation from chapter
2 and chapter 3, since the isolated compounds exhibit significant inhibition activity
against the alpha glucosidase enzyme and inducing cellular glucose uptake activity.
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Figure 4-4: Visual representation of levulinic acid analog on fumarase enzyme, where the binding showed at the
formation of a hydrogen bonds between the group at C-1 and C-4 with the amino acid residues ASN 141, SER 140 and
ASN 135.
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Figure 4-5:Visual representation of isolated compound SAA4 binding on the fumarase enzyme, where the binding
showed at the formation of a hydrogen bond between the carboxylate group with the amino acid residues SER 140,
and hydrogen bond between the hydroxyl group with the amino residue ASN 141.
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Figure 4-6: Visual representation of AN21 analog on the fumarase enzyme.
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Figure 4-7: Visual representation of SAA3 analog on the fumarase enzyme, where the binding showed at the formation
of a hydrogen bond between the oxygen of carbonyl group at C-1 with the amino acid residues SER 140.
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Figure 4-8: Visual representation of SAA3 isolated compound from cissus rotundifolia on isocitrate dehydrogenase
enzyme, where the binding showed at the formation of a hydrogen bonds between the methoxy group with the amino
acid residues LYS 171 and TYR 173.
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Figure 4-9: Visual representation of SAA4 isolated compound from cissus rotundifolia on isocitrate dehydrogenase
enzyme, where the binding showed at the formation of a hydrogen bond between the methoxy group with the amino
acid residues HIS 301.
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Figure 4-10: Visual representation of analog AN21 on malate dehydrogenase enzyme. AN21 analog formed three
hydrogen bonds between the amide group at C-3 with the amino acid residue ASN118; in addition, two hydrogen
bonds occurred between the oxygen of carbonyl group at C-1 with two amino acid residues: THR211 and ARG80,
respectively.
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Figure 4-11: Visual representation of isolated compound SA19 on malate dehydrogenase enzyme. SA19 represents a
hydrogen bond interaction on the malate dehydrogenase enzyme between the hydroxyl group at C-2 with the amino
acid reside ALA223.
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Figure 4-12: Visual representation of levulinic acid analog on isocitrate dehydrogenase enzyme, where the binding
occurred at the formation of a hydrogen bonds between the group at C-1 and C-2 with the amino acid residues
PHE169, GLU306 and TYR173.
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Figure 4-13: Visual representation of SAA3 analog on phosphoenolpyruvate protein kinase enzyme (PECK), where the
binding showed at the formation of a hydrogen bonds between the group at C-1 and C-3 with the amino acid residues
VAL335, SER286 and LYS290.
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5.1

Appendix

Structure elucidation NMR spectrum
1

H-NMR, 13C-NMR and 2D-NMR were conducted using Bruker AVANCE-400

MHz and 600 MHz NMR spectrometer in deuterated chloroform (CDCl3) using
tetramethylsilane (TMS) as the internal standard; chemical shifts are given in ä (ppm)
values.

Figure 5-1 : 1H -NMR Spectrum of 1 in CDCL3
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Figure 5-2 : 13C -NMR Spectrum of 1 in CDCL3
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Figure 5-3 : 1H -NMR Spectrum of 3 in CDCL3

Figure 5-4 : 13C -NMR Spectrum of 3 in CDCL3
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Figure 5-5 : DEPT135 -NMR Spectrum of 3 in CDCL3
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Figure 5-6 : 1H -NMR Spectrum of 4 in Acetone
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Figure 5-7 : 13C -NMR Spectrum of 4 in Acetone

127

Figure 5-8 : DEPT90 -NMR Spectrum of 4 in Acetone

